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  ABSTRACT 
 
This thesis describes an ancillary project to the Early Diagnosis of Mesothelioma and 
Lung Cancer in Prior Asbestos Workers study and was conducted to determine the 
effects of asbestos exposure, pulmonary function and cigarette smoking in the prediction 
of pulmonary fibrosis. 613 workers who were occupationally exposed to asbestos for an 
average of 25.9 (SD=14.69) years were sampled from Sarnia, Ontario. A structured 
questionnaire was administered during a face-to-face interview along with a low-dose 
computed tomography (LDCT) of the thorax. Of them, 65 workers (10.7%, 95%CI 
8.12—12.24) had LDCT-detected pulmonary fibrosis. The model predicting fibrosis 
included the variables age, smoking (dichotomized), post FVC % splines and post-
FEV1% splines.  This model had a receiver operator characteristic area under the curve 
of 0.738. The calibration of the model was evaluated with R statistical program and the 
bootstrap optimism-corrected calibration slope was 0.692. Thus, our model demonstrated 
moderate predictive performance. 
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CHAPTER I- INTRODUCTION 
1.1 Introduction  
Asbestos is the commercial term for a group of silicate minerals with fibrous crystal 
structures (American Thoracic Society, 2004). The two basic families of asbestos are 
serpentines and amphiboles.  Chrysotile is the only member of the serpentine family, 
while crocidolite, amosite, actinolite, anthophyllite and tremolite belong to the 
amphiboles. Inhalation of asbestos fibers is a well-recognized cause of both malignant 
and non-malignant diseases of the lung parenchyma and pleura.  Asbestos has three main 
effects on health: mesothelioma of the pleura or peritoneum, pulmonary cancer and 
asbestosis. Asbestos-related diseases have lengthy latent periods ranging from 15-20 
years for asbestosis and greater than 40 years for mesothelioma (American Thoracic 
Society, 2007; The Spanish Society of Pulmonology, 2005; Cugell & Kamp, 2004; 
Bartrip, 2004). Today, even with stringent regulation of asbestos use and the 
disappearance of almost all asbestos-containing products from the market in the 
developed world, asbestos-related disease remains a concern for older workers exposed to 
asbestos. The long latency between initial exposure to asbestos and subsequent biological 
consequence means that new cases of asbestos-related disease will continue to be present 
as a result of previous exposures.  All types of asbestos are associated with these 
diseases. Chrysotile fibers are thought to be less harmful than the amphiboles because 
they are more readily broken down and removed by the lung (Cugell & Kamp, 2004).   
 The focus of this study was pulmonary fibrosis, also known as asbestosis. 
According to the American Thoracic Society (ATS), asbestosis is simply diffuse 
interstitial pulmonary fibrosis due to the inhalation of asbestos fibers (American Thoracic 
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Society, 2004). For asbestosis to develop, the process requires the inhalation of 
considerable numbers of asbestos fibers, and usually over a long period of time. The most 
recent ATS guidelines require evidence of causation as demonstrated by one or more of 
the following criteria: 1) occupational and environmental exposure with plausible 
latency, 2) markers of exposure such as pleural plaques and 3) recovery of asbestos from 
tissue.  The ATS recognizes both chest x-ray and computed tomography as useful in the 
diagnosis of asbestos-related diseases. Currently, evidence of functional impairment is 
not required for the diagnosis of asbestosis, though it is considered an important part of 
overall evaluation.  Evidence of functional impairment includes symptoms and signs such 
as crackling, change in ventilatory function (restrictive pattern), impaired gas exchange 
(DLCO), and detection of inflammation (American Thoracic Society, 2004).   
 Though the incidence of asbestos-related diseases in the general population is 
low, their impact in exposed populations, mainly through occupation, is severe. The 
incidence of mesothelioma of the pleura in Canada (excluding Quebec) between 1984 
and 1996 was 11.3 cases per million population in men and 1.64 cases per million in 
women (Sub-Committee on the Epidemiology of Asbestos Related Diseases, 2004).  The 
incidence in Quebec is significantly higher due to the presence of numerous asbestos 
mining regions within the province.  The incidence for Quebec was 15.3 cases per million 
population (Sub-Committee on the Epidemiology of Asbestos Related Diseases, 2004).  
Determining the incidence or prevalence of asbestosis has varied and been 
difficult to establish due to difference in duration, intensity and type of exposure to 
asbestos.  Among miners exposed to chrysotile in Quebec, there was a 5% prevalence of 
small patchy opacities after exposure to 20 fiber-years, in which exposure was calculated 
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individually for each participant on the basis of work history and industrial hygiene 
measurements (The Spanish Society of Pulmonology, 2005).      
 Imaging, whether chest radiography or computed tomography, contributes to the 
evaluation of asbestos-related disease on many levels: in diagnosis (American Thoracic 
Society, 2004), for the quantification of disease extent (American Thoracic Society, 
2004; The Spanish Society of Pulmonology, 2005), as part of medico-legal claims 
evidence (Copley, Gary Lee, Hansell, Sivakumaran, Rubens, Taylor, Rudd, Musk & 
Wells, 2007), to screen high-risk individuals for cancer and for distinguishing other (non 
asbestos-related) causes of pulmonary dysfunction (Copley et al., 2007).  Though 
radiological evaluations of asbestos-exposed individuals are relatively sensitive and 
reproducible for these purposes, frequent use is questionable owing to the radiation 
burden and high economic cost (Xaubet, Agusti, Luburich, Roca, Monton, Ayuso, 
Barbera, & Robriguez-Roicin, 1998).  It has been reported that pulmonary dysfunction 
precedes chest x-ray findings of pneumoconiosis (occupational lung disease), suggesting 
the importance of pulmonary function tests in screening for early disease and prediction 
of subsequent disease (Tonori, Nitsuya, Sato, Sugiura, Miyake, & Aizawa, 2005).  A 
second potential contribution of pulmonary function tests in asbestos-exposed individuals 
is in quantifying the extent of disease (Xaubet et al., 1998).  According to various studies, 
pulmonary function tests can offer significant information about the extent of 
abnormalities, and thus, indicate that it is possibly not necessary to perform tests of high 
radiation burden routinely for quantification of disease severity (Neri, Boraschi, 
Antonelli, Falaschi, & Baschiere; Sette, Neder, Nery, Kavakama, Rodrigues, Terra-Filho, 
Guimaraes, Bagatin, & Muller).  Correlation studies between radiological findings and 
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pulmonary functions tests have also been used to determine the proportion of pulmonary 
deficit attributable to specific disorders such as fibrosis, diffuse pleural thickening and 
emphysema (Copley, Wells, Rubens, Chabat, Sheehan, Musk, & Hansell). 	  
With the advent of low-dose CT techniques and single breath-hold scanning 
capabilities, there has been interest in the use of CT as a mass screening method for 
patients with high risk for developing lung cancer, including asbestos-exposed 
populations. Though several studies have correlated chest x-ray and high resolution 
computed tomography with pulmonary function, no work to date has been done to 
correlate low-dose computed tomography changes with pulmonary function tests in 
asbestos-exposed individuals.   
The interaction between smoking and asbestos is a very important issue in a number 
of lung diseases, most notably lung cancer. Some data suggests synergy between asbestos 
and smoking in the development of pulmonary fibrosis however current data is 
preliminary and inclusive (Alfonso et al., 2004; Neri et al., 1996; Wang et al., 2006). For 
this reason further exploration is needed including a comprehensive interaction analysis, 
which has not been performed to date. 
1.2 Study Aims    
This study has several aims. The first is to determine the prevalence of pulmonary 
fibrosis in a well described asbestos-exposed occupational cohort from Sarnia, Ontario, 
Canada.  The second is to assess multiple predictors of pulmonary fibrosis found by low-
dose CT in a prediction model, specifically past asbestos exposure, pulmonary function 
indices (FVC, FEV1, FEV1/FVC, TLC, and DLCO) and smoking status. The third aim is 
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to determine if there is an interaction between asbestos exposure and smoking that affects 
the risk of pulmonary fibrosis.  
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CHAPTER II- REVIEW OF THE LITERATURE 
 
2.0 Overview 
This chapter provides the background and rationale for this study. The chapter 
begins with a modern history of asbestos, the impact of asbestos-related disease and an 
overview of the properties of asbestos fibers. Particular attention is given to asbestos-
induced fibrotic disease involving both the pleura and pulmonary interstitium.  A brief 
explanation of the most common imaging techniques used for asbestos-exposed persons 
including chest radiography and computed tomography is given.  Lastly, a review of 
radiological-functional correlation studies in asbestos exposed individuals is presented.  
 
2.1 A Global History of Asbestos  
In 1907, the first well documented fatal case of an asbestos-related disease, 
pneumoconiosis, an inflammation of the lung characterized by fibrosis and reduction of 
lung function caused by inhalation of asbestos fibers, was described by Dr. Montague 
Murray in the United Kingdom (The Spanish Society of Pulmonology, 2005; Cugell & 
Kamp, 2004). The term for this condition, asbestosis, was not coined until 1925 by 
Thomas Oliver (Bartrip, 2004). In 1930, Merewether and Price published an article in 
which one fourth of 363 factory workers in England had signs of asbestosis 
(Mereweather & Price, 1930).  More importantly, Merewether believed the disease was 
preventable and anticipated dust control would increase the length of time before 
developing fibrosis. He hypothesized if asbestos exposure was eliminated there would be 
a total disappearance of the disease (Bartrip, 2004). The result of the Merewether Report 
was the first dust-control regulations for Great Britain in 1931 (Cugell & Kamp, 2004; 
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Parkes, 1974). Similar regulations were not imposed in the United States until 1971 
(Cugell & Kamp, 2004).   
The first indication that asbestos could also be a human carcinogen was in 1935 
when there was a reported association between asbestosis and lung cancer (Bartrip, 
2004). In 1955, Doll established enough information that most informed observers 
believed a causal association between asbestos exposure and lung cancer (Bartrip, 2004; 
Doll, 1960). However, Doll believed that the Asbestos Industry Regulations had greatly 
reduced the risk of lung cancer for those who worked in Britain’s asbestos factories, and 
an asbestos ban was not necessary (Bartrip, 2004).  
In the 1960’s a third asbestos-related disease was reported, mesothelioma 
(Wagner, Sleggs, & Marchand, 1960; Niklinki, Niklinska, Chyczewska, Laudanski, 
Naumnik, Chyczewski, & Pluygers, 2004). A paper by Wagner et al. established a 
possible association between the development of mesothelioma of the pleura and 
exposure to asbestos dust in people living in the Cape asbestos fields of South Africa 
(Bartrip, 2004; Wagner et al., 1960).  Evidence  revealed that hazards of asbestos were 
not confined to the  exposed asbestos workers but also other users of asbestos products 
and those who lived near asbestos factories (Bartrip, 2004; Selikoff, Hammond, & Churg, 
1964; Selikoff, Hammond, & Churg, 1965).  These events led to a revisiting of the 1931 
dust-control regulations in Britain resulting in the Asbestos Regulation of 1969.  This 
allowed the continued use of asbestos only if maximum allowable concentrations of 
asbestos dust were not exceeded and other precautions were observed.  Asbestos dust was 
defined as dust containing asbestos to such an extent as is likely to cause danger to the 
health of employed persons, implying a quantitative threshold.  Occupational exposure to 
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crocidolite should not exceed 0.2 fibers/ml of sampled air when measured over any 10 
minute period and for other asbestos 2 fibers/ml measured over a four hour period.  This 
amount of allowable crocidolite was so low its use was eliminated.  Finally, in July 1999 
the European Commission announced a European Union ban on all remaining chrysotile 
use which was implemented in October 1999. 	  
2.2 Asbestos in Canada 	  
Industrial consumption of asbestos in Western Europe, Scandinavia, North 
America and Australia peaked in the 1970’s when the gradual recognition that this 
“magic mineral” was associated with the occurrence of several serious health 
consequences led to a strict curtailment of asbestos’ industrial use (Niklinki et al., 2004; 
Tossavainen, 2004).  The worldwide production of asbestos products in 1975 exceeded 
five million tons while currently the level is approximately two million tons, of which 
90% is chrysotile (Tossavainen, 2004).    
Canada exported approximately 300,000 tons of asbestos in 2000 (Brophy, Keith, 
Schieman, 2007).  According to the International Labor Organization, between 1983 and 
2006, national asbestos bans, with minor exceptions, have been successfully implemented 
in thirty-nine countries worldwide in accordance with measures of health protection in 
international trade agreements (Tossavainen, 2004; Brophy et al., 2007).  The Canadian 
government challenged these regulations at the World Trade Organization (WHO) 
(Tossavainen, 2004; Brophy et al., 2007, World Trade Organization, 2001). Despite an 
overwhelming consensus from major health organizations such as the International 
Agency for Research on Cancer (IARC) and the WHO, that all forms of asbestos are 
human carcinogens and have no safe threshold at which there is no increased risk of 
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cancer, the Canadian federal government continues to advocate the controlled use of 
chrysotile (Brophy et al., 2007).  
In Canada, occupational health and safety regulations fall under provincial 
jurisdiction, with each province setting its own standards. In Ontario, the all type asbestos 
exposure standard is 0.1 fibers /ml (Brophy, 2007; World Trade Organization, 2006).   
2.3 The Impact of Asbestos-Related Disease 
In 1987 the U.S. National Institute of Health estimated that approximately eleven 
million individuals had been exposed to asbestos in the United States since 1940 
(Manning, Vallyathan, & Mossman, 2002; NIH Research Findings, 1978). The overall  
incidence of mesothelioma in the general population was extremely low.  According to 
the data from the Surveillance, Epidemiology and End Results Program (SEER), the 
incidence of mesothelioma in the United States is 14 to 15 cases per million population of 
men (Price & Ware, 2004). This amounts to 1750 males diagnosed with mesothelioma 
each year in the U.S. The incidence in women is about two cases per million population, 
which is, approximately 250 new cases of mesothelioma each year (Price & Ware, 2004). 
The incidence of mesothelioma shows an age effect, meaning the incidence increases 
with age (Price & Ware, 2004).  Mesothelioma incidence also shows a birth-cohort effect. 
Figure 1 shows the lifetime risk for males is a maximum of 2.1 X 10-3 for the 1925-1929 
birth cohort and then declines sharply for subsequent cohorts (Price & Ware, 2004). Male 
members from this cohort would have been at work during the years 1930-1960, a period 
of increasing and maximum asbestos consumption in the United States. Table 1 shows 
the results of a recent study which estimated the incidence of mesothelioma based on the 
global use of asbestos.  
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Figure 1:  Lifetime Probability (risk) of Mesothelioma (Pleural + Peritoneal) and 95% 
Confidence Intervals Based on a Birth-Cohort and Age Model Estimated from 2003 
Surveillance, Epidemiology, and End Results Program data covering 1973-2000 (Price & 
Ware, 2004)  
 
In a study comparing the incidence rates of mesothelioma of the pleura in Quebec 
compared to those in the rest of Canada between 1984 and 1996, the incidence rate 
(adjusted for age and year) of mesothelioma of the pleura in men was 11.3 cases per 
million population in Canada outside of Quebec.  The incidence rate for Quebec was 1.35 
(95% CI = 1.20 – 1.46) times higher than those of Canadians in all other provinces 
combined at 15.3 cases per million population.  The incidence rate of mesothelioma of 
the pleura in women was 1.64 cases per million in Canada, excluding Quebec and 3.14 
cases per million in Quebec (Sharpe & Hardt, 2006).   
Based on the Canadian Agricultural Injury Surveillance Program asbestos-related 
deaths accounted for 61% of death from occupational diseases and 31% of all workplace 
fatalities in Canada in 2005 (Sharpe & Hardt, 2006). The fatality rate from asbestos is up 
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from 0.4 per 100,000 workers in 1996 to 2.1 per 100,000 in 2005 (Sharpe & Hardt, 
2006). The number of Canadian men who receive a diagnosis of mesothelioma each year 
has been steadily increasing over the past twenty years, from 153 cases in 1984 to 344 
cases in 2003 (Statistics Canada, 2008). The number of new cases of pleural 
mesothelioma in Ontario males rose from 20 in 1982 to 72 in 2002 (Cancer Care Ontario, 
2004).  
In the United Kingdom, France, and Australia, the mesothelioma incidence is not 
expected to peak until the 2010-2020 period (Tossavainen, 2004). In Canada, where the 
production and use of asbestos is not banned, the number of deaths related to 
occupational asbestos exposure is not expected to peak until after 2010-2020 due to the 
lengthy latent period of asbestos-related diseases (Tossavainen, 2004). 
 
Table 1. National Mesothelioma Incidence  
(Tossavainen, 2004; Sub-Committee on the Epidemiology of Asbestos-Related Disease, 
2004)  
 
Country Mesothelioma Incidence 
 Cases (year) Cases/million/year 
Australia 465 (1997) 35 
Finland 74 (1999) 18 
France 750 (1996) 16 
Germany 1007 (1997) 15 
Great Britain 1595 (1999) 33 
Italy 930 (1995) 19 
Netherlands 377 (1997) 30 
New Zealand 50 (1996) 18 
Norway 48 (1995) 14 
Sweden 105 (1996) 15 
United States 2800 (2000) 14 
Canada (excluding Quebec) N/A (1996) 11.3 
Quebec N/A (1996)  15.3 
  
The incidence of asbestosis in Canada has not been clearly established.  The 
majority of studies undertaken are not free of bias or have not followed a sufficiently 
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large cohort over a long enough period of time.  The most realistic estimate of the 
prevalence of asbestosis is between 1% and 5% of asbestos-exposed workers (The 
Spanish Society of Pulmonology, 2005). The prevalence of radiologically documented 
asbestosis varies considerably in studies of asbestos-exposed workers.  This 
inconsistency may be due to differences in duration, intensity and type of asbestos 
exposure between workplaces.  However, even when exposure is calculated individually 
for each member of a cohort based on work history and industrial hygiene measurements, 
there are still considerable differences in observed associations due to fiber type and the 
industrial process (Liddell & McDonald, 1980; Lilis, Miller, Godbold, Chan, Benkert, & 
Selikoff, 1991). In a recent study modeling the prevalence and incidence of fibrosis and 
pleural plaques in asbestos-exposed populations for screening found 6% of subjects had 
interstitial changes compatible with asbestosis on CT-scan (Paris, Martin, Letouneux, & 
Wild, 2008).  In a study of former crocidolite asbestos workers in Western Australia the 
prevalence of radiographic asbestosis was as high as 17.6% (Alfonso, Fritschi, de Klerk, 
Olsen, Sleith, & Musk, 2004).   A screening study for lung cancer found 85 cases of 
asbestosis out of 2857 persons with asbestos-related occupational disease (Tiitola, 
Kivisaari, Huuskonen, Mattson, Koskinen, Lehtola, Zitting, &Vehmas, 2002)  
2.4 The Impact of Asbestos-Related Diseases in Canada 
In Canada there have been significant changes in the prevalence of occupational 
respiratory disease over the past thirty years.  Though Canada is rich in minerals and 
mining continues to be common in many parts of the country, pneumoconiosis has 
declined as a cause of mortality and hospital admission (Figures 2 and 3). Yearly hospital 
admission rates due to pneumoconioses have been only 1 or 2 per 100,000 population 
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since the early 1990s, with mortality rates below 0.25 per 100,000 population, and less 
than 0.5 per 100,000 population among those 35 years of age and older. These trends are 
similar to those reported in the United States and may reflect improved occupational 
hygiene conditions in mines, better dust control, and better use of respiratory protective 
measures.  
However, this decline in admission rates for all pneumoconiosis is not occurring 
for asbestosis over time. This would be expected if better preventive measures at work 
which involves asbestos exposure were being implemented.   
 
Figure 2:  Pneumoconioses Hospitalization Rates (per 100,000), Canada*, 1987-
2004 
(Age-Standardized to 1991 Canadian Population) (Life and Breath: Respiratory 
Disease in Canada, 2007)  
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Figure 3: Pneumoconioses Mortality Rates (per 100,000), Canada, 1987-2004  
(Age- Standardized to 1991 Canadian population) (Life and Breath: Respiratory 
Disease in Canada, 2007)   
 
 
Figure 4: Pneumoconioses and Hypersensitivity Pneumonitis Hospitalization 
Rates  
(per 100,000), Canada*, 1987-2004, aged 35+ years, (Age-Standardized to 1991 
Canadian population) (Life and Breath: Respiratory Disease in Canada, 2007) 
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Given the long latency of asbestosis and reduced exposure in the past twenty 
years, a further decline in hospitalizations would be expected. What other explanations 
are there for this finding? The answer to this is yet to be found.  
Mesothelioma is a malignant tumor affecting the lining of the chest or abdomen 
caused by asbestos exposure. Figures were not available for mesothelioma under the ICD 
coding system until the introduction of ICD 10 codes in 2001, and there are no current 
national estimates for this complication of asbestos exposure, as ICD 10 codes were not 
implemented in all provinces until 2006. However, the numbers of (pleural) 
mesothelioma cases reported by Cancer Care Ontario (Figure 5) have demonstrated the 
marked rise associated with asbestos exposure decades earlier.  
 
 
Figure 5: Ontario Mesothelioma Incidence Rate, 3 Year Moving Average, by Sex, 
1980-2004 (Life and Breath: Respiratory Disease in Canada, 2007) 
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A study by Teschke et al., investigated whether there were previously 
unrecognized sources of asbestos exposure in British Columbia, Canada using incident 
cases of mesothelioma (n=51) and population-based controls (n=154).  The subjects were 
interviewed about occupational histories and asbestos-specific exposures.  When 
excluding subjects who worked in occupations which were a prior at risk for 
mesothelioma, three groups remained of interest: non-asbestos miners (OR=9.6, 
95%CI=1.8-53), bricklayers (OR=5.4, 95%CI=1.0-28) and construction laborers 
(OR=2.8, 95%CI=0.7-10.5).  The wide confidence intervals suggest cause for concern, 
however considering that sample size when excluding those a prior at risk was as small 
as 19, the trend toward significant is impressive. Teschke et al. point out that despite this 
problem the major occupations at risk for mesothelioma were easily detected in their 
study (Teschke, Morgan, Checkoway, Granklin, Spinelli, Belle, & Weiss, 1997).   	  
2.5 Types of Asbestos  
Asbestos is a naturally occurring group of hydrated silicate fibrous minerals. 
Asbestos is traditionally subdivided into two groups: serpentines (curly fibers) and 
amphiboles (straight, needle-like fibers).  Chrysotile is the only commercially used 
serpentine and has many industrial applications.  It is long, curly, pliable and heat 
resistant; however it is damaged in acidic environments (American Thoracic Society, 
2004; The Spanish Society of Pulmonology, 2004; Manning et al., 2002). Chrysotile 
fibers are made of fibrils with a layered silicate structure formed of cylindrical tubes.  
Due to its physical and chemical properties, this serpentine form of asbestos is most 
suitable for making fabrics and other flexible products.  It is estimated that 90 – 95% of 
all past commercially used asbestos in North America has been chrysotile with most of 
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this being derived from Canadian and Russian mines (American Thoracic Society, 2004; 
Manning et al., 2002).    
The second group of asbestos fibers is amphiboles. Amphibole fibers include 
amosite (brown asbestos), crocidolite (blue asbestos), tremolite, actinolite, and 
anthophyllite. They are characterized by their short straight needle-like appearance, lack 
of pliability and relative resistance to acid. The basic subunit of amphiboles is a silicon 
dioxide tetrahedron arranged in parallel chains and linked laterally by cations.  Among 
the five amphiboles, the most commonly used are amosite and crocidolite. Amphiboles 
have superior chemical and physical stability and have been used in the production of 
asbestos-cement pipe, floor tiles and when mixed with chrysotile a vast array of friction 
products, gaskets, roofing, insulation, and fire-proofing material (American Thoracic 
Society, 2004; Manning et al. , 2002).    
Amphiboles and chrysotile are different from each other in terms of their 
chemical and physical composition, shapes, sizes, durability and pulmonary penetration 
abilities, and thus their potency to increase health risk differ.  Chrysotile fibers are less 
harmful than amphiboles, partly because they are more readily broken down and removed 
from the lung (Cugell & Kamp, 2004).  Of those fibers which remain in the lung, some 
become coated with ferritin and then form asbestos bodies (Roach, Davies, Attanoos, 
Crane, Adam, Wilson, Dee, & Hansell, 2000). 
2.6 Measuring Asbestos Exposure   
The accuracy of exposure assessment is a major determinant of the 
informativeness of a study and the validity of risk estimates drawn from it. The 
retrospective assessment of occupational asbestos exposure has several important aspects 
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to consider. The pulmonary response to asbestos is thought to be proportional to the 
amount and duration of exposure that contributes to the retention of fibers in the distal 
airspace.  Therefore there are three major considerations for asbestos exposure 
assessment: 1. exposure intensity (concentration of asbestos fibers), 2. latency period 
(time since first exposure), and 3. duration of exposure. A recent study by Paris et al., 
2008 found that time since first exposure and exposure intensity were predictive of 
asbestosis and pleural plaques, but not duration of exposure (Paris et al., 2008).  
The type of asbestos involved in exposure (chrysotile, crocidolite, amosite, etc.), 
if known, should be considered given that chrysotile fibers are potentially less harmful 
than the amphiboles (Cugell & Kamp, 2004).  Also, measures taken to protect workers 
are important to include in analysis when attempting predictions of risk or studying 
etiology.   
In occupational epidemiology, retrospective exposure assessment offers certain 
advantages, but also poses several major challenges. In the case of asbestos exposure, 
exposed individuals are mainly scattered in specific worksites therefore, a study centered 
in a geographical area where workers reside is logistically simpler than assembling a 
prospective cohort study.  The retrospective case-control also allows the evaluation of 
multiple exposures, including occupational and residential exposures, and lifestyle factors 
which may confound or interact with exposure-disease associations.  
The main challenge of asbestos exposure measurement is the method by which 
data is gathered.  There is rarely a quantitative measurement of asbestos exposure on 
record therefore, retrospectively collected detailed occupational histories, job tasks or 
specific recall to asbestos exposures are used. There are several potential sources of error 
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in the collection of occupational exposures such as misclassification, incomplete data on 
concentrations or work time, poor sources of data (e.g. statement of usual occupation of 
death certificates) and recall bias.  Information on level of exposure is only available on 
rare occasions because dust levels in the workplace were not measured until the late 
1980’s. Owing to the lengthy latent period, incident asbestos-related disease is often 
associated with exposure that occurred before such levels were monitored (American 
Thoracic Society, 2004).  Due to the lack of documentation of actual exposure in the past, 
the use of crude exposure classifications is often necessary.  The most common 
retrospective exposure assessment methods are: use of occupational history to infer 
exposure, known as job exposure matrices (JEMs); self reported exposures; and expert 
assessment of exposures.  Each exposure assessment method has strengths and 
limitations.  
JEMs combine information across occupation and industry in an attempt to 
provide greater accuracy as to exposure status.  JEMs attempt to relate specific jobs to 
exposure presence, intensity, frequency and/or probability, assigning an exposure 
category based on standardized occupational and industrial codes.  In 1991 this approach 
was taken in developing the National Occupational Hazard Survey Job Exposure Matrix 
(NOHS-JEM).  The NOHS was carried out between 1972 and 1974 in the United States, 
collecting information at the work site on chemical and physical agents in a wide range of 
occupations and industries.  The major drawback of using the NOHS-JEM is that it is 
based on exposure conditions in 1972-1974, and these may differ from periods before and 
after this time interval (Sieber, Sundin, Frazier, & Robinson, 1991).  It was found that 
expert assessment identified more asbestos exposure than the NOHS-JEM, which the 
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NOHS-JEM did not classify many occupation-industry couplets, and no assessment of 
intensity was made (Cicioni, London, Garabrant, Berstein, Phillips, & Peters, 1991).  A 
major limitation of JEMs is their inability to account for variability in exposures within 
jobs or across time (Teschke, Olshan, Daniels, De Roos, Parks, Schulz, & Vaughan, 
2002).  Therefore JEMs are vulnerable to non-differential misclassification due to these 
with-in job variations in exposure (Benke, Sim, Fritschi, Aldred, Forbes, & Kauppinen, 
2001). These limitations have decreased enthusiasm for generic JEMs and promotes the 
use of study specific JEMs (Teschke et al., 2002).   A new JEM has been developed to 
provide a link between job title or activity reported in a work history, the type and length 
of asbestos fibers, and intensity of exposure which may be all useful in exposure 
reconstruction in the future (Rice & Heineman, 2003).    
 The use of occupational hygienists is thought to be the gold standard of exposure 
assessment. An occupational hygienist (or panel), with no prior knowledge of disease 
status, reviews work information provided from questionnaires administered to study 
participants.  Hygienists evaluate completeness of work histories and assign relative 
exposure intensity for any job where there was a probability of exposure to asbestos 
(Nam, Rice, & Gail, 2005; Benke et al., 2001).  High cost considerations for hygiene 
panels prevent many asbestos-related studies from their use in ascertaining exposure 
status (Benke et al., 2001).  Experts do have an advantage over self reported exposures by 
subjects due to training, understanding the mechanisms of occupational exposures, and 
knowledge on where to find data. The major limitation of experts is that they rely heavily 
on a detailed occupational history because they are unlikely to be aware of specific work 
conditions for individual subjects (Teschke et al., 2002).  
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Questionnaires are commonly used to ask about subject’s occupational history, 
use of specific agents, trade name products or specific type of asbestos. Though studies 
that assess exposure with direct questions to participants, such as “Were you ever 
exposed to asbestos?”, are prone to recall bias and may be vulnerable to widely varied 
interpretations among participants of what constitutes exposure, data derived in this crude 
fashion can still yield useful information (Teschke et al. , 2002).  A study comparing 
next-of-kin assessment, expert assessment and the use of the NOHS-JEM found that 
disease-exposure odds ratios based on next-kin respondents are inflated by recall-bias, 
whereas those from the NOHS-JEM are attenuated.  Also NOHS-JEM exposure 
categorization based on next-of-kin data predicted asbestos levels that matched expert 
assessment better than only NOHS-JEM (Nam et al., 2005).  Though information from 
proxy respondents is regarded as inferior to self-reports for occupational exposures, for 
rapidly fatal diseases such as mesothelioma, next-of-kin respondents may be an important 
and only source of data.  
In summary, among the asbestos exposure assessment methods in use today, 
expert assessment is the best approach, however it can also have low validity and 
reliability if there is not proper training of the expert, and if not enough information is 
provided in the detailed occupational history of subjects.  However, all exposure 
assessment methods, whether by experts or self-report have limitations and can have low 
validity and reliability.   
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2.7 Pulmonary Function Tests 
 A brief description of pulmonary function tests and their relevance in asbestos-
exposed individuals is presented and is followed by a description of known functional 
deficits in specific asbestos-related diseases.    
Pulmonary function tests provide objective and quantifiable measures of lung 
function. They are used to evaluate and monitor diseases that affect the lung and heart, to 
monitor the effects of environmental, occupational and drug exposures, to assess risks of 
surgery, and to assist in evaluations performed before employment or for insurance 
purposes.	  	  According to the 2004 American Thoracic Society (ATS) guidelines, 
demonstration of functional impairment is not required for the diagnosis of a 
nonmalignant asbestos-related disease, but where present should be documented as part 
of a complete evaluation (American Thoracic Society, 2004).   
It has been reported that pulmonary dysfunction precedes chest x-ray findings of 
pneumoconiosis (occupational lung disease), suggesting the importance of pulmonary 
function tests in screening for early disease (Tonori et al., 2005).  A second potential 
contribution of pulmonary function tests in asbestos-exposed individuals is in quantifying 
the extent of disease (Xaubet et al., 1998), and to assess the progression of lung disease 
(Al-Ashkar, Mehra, & Mazzone, 2003).  Though radiological evaluations of asbestos-
exposed individuals are relatively sensitive and reproducible for determining the extent of 
disease, their frequent repetition is questionable owing to the radiation burden and their 
high economic cost (Xaubet et al., 1998).  According to various studies, pulmonary 
function tests can offer significant information about the extent of abnormalities, and 
thus, indicate that it is possibly not necessary to perform tests of high radiation burden 
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routinely for quantification of disease severity (Neri et al., 1996, Sette et al., 2004). This 
will be discussed in further detail in Section 2.11 Radiological-Functional Correlation.    
Evaluation of subjects with suspected asbestos-related disease should include a 
panel of tests including spirometry, measurements of lung volume and diffusion capacity 
for carbon monoxide (DLCO) (American Thoracic Society, 2004).  Spirometry measures 
changes in lung volume over time during forced breathing maneuvers. The patient is 
instructed to take a full inspiration and then exhales as forcefully as possible for as long 
as possible.  The total volume of air expired is the forced vital capacity (FVC).  The air 
expired in the first second of forced expiration is FEV1.  FVC and FEV1 are expressed as 
both absolute volumes and percent predicted values, with predicted values based on 
healthy volunteer data which are matched to the patient’s age, height, sex and race.  The 
FEV1/FVC is a direct ratio of the patient’s own values.   
 The DLCO measures the ability of the alveolar capillary membrane to diffuse 
gases.  The patient inhales a harmless composite gas (10% helium, 0.3% carbon 
monoxide) and is instructed to hold their breath for 10 seconds.  The exhaled breath is 
then analyzed for dilution of helium and CO.  There are three major pulmonary disorders 
which may cause a decreased in DLCO, obstructive airway disease (i.e. emphysema, 
cystic fibrosis), interstitial lung disease (i.e. pulmonary fibrosis), and pulmonary vascular 
disease (Al-Ashkar et al., 2003). DLCO can also be adjusted for alveolar volume and is 
called DLCO/VA.   
  Lastly, total lung capacity (TLC) can be obtained by four methods: nitrogen 
washout, helium dilution, body plethesmography (the gold standard TLC measurement, 
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although it is complex and expensive), and rough estimation using chest x-ray during 
maximal expiration.   
 Obstructive lung disease is characterized by decreased airflow during expiration.  
Some classic examples of obstructive lung disease are asthma, chronic bronchitis, and 
emphysema.  Obstruction is defined as having an FEV1 less than 70-80 % of the 
predicted value.  FVC may be normal or decreased, but to a lesser degree than FEV1.  An 
FEV1/FVC of less than 70% is also characteristic of obstruction.   DLCO generally does 
not decrease in most obstructive lung diseases with the exception of emphysema. A 
DLCO of less than 74% predicted is mild impairment and less than 40% predicted severe 
impairment.   
Restrictive lung disease is characterized by a decreased lung volume, defined as 
having a TLC less than 80% predicted.   There are extrinsic and intrinsic causes of 
restrictive lung disease.  Extrinsic causes of restrictive lung disease are decreased chest 
wall compliance, which occurs in obesity, and weakening of respiratory muscles due to 
neuromuscular disorders. Intrinsic causes are those which occur within the lung tissue 
such as interstitial lung disease or congestive heart failure.  FEV1 and FVC are both 
reduced in restriction; however FEV1/FVC remains normal or increased. A decreased 
DLCO is seen in significant interstitial lung disease (e.g. pulmonary fibrosis), but 
remains normal when there are other causes of decreased lung volumes (such as obesity, 
pleural scarring, neuromuscular disease). See  Table 2 and Table 3 for a summary of 
pulmonary function test variables and their relation to pulmonary disorders.   
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Table 2. Obstructive and restrictive patterns   
(Adapted from Al-Ashkar et al., 2003)   
 
Measurement  Obstructive Pattern Restrictive Pattern 
Forced vital capacity 
(FVC)  
Decreased or normal Decreased 
Forced expiratory 
volume in 1 second 
(FEV1)  
Decreased Decreased or normal  
FEV1/FVC ratio Decreased  Normal or increased  
Total lung capacity 
(TLC) 
Normal or increased Decreased  
 
2.8 Diseases Caused By Asbestos Exposure 
Epidemiologic and animal studies have indicated several well-recognized benign 
and malignant diseases of the lung parenchyma and pleura associated with inhaled 
asbestos exposure. Asbestos fibers have a natural, unexplained predilection to the pleura, 
the outer covering of the lungs (visceral pleura) and the inner covering of the chest cage 
(parietal pleura). It is at the pleural surface where the effect of asbestos exposure often 
occurs. There are four distinct benign pleural reactions to asbestos: (1) pleural effusion, 
(2) pleural plaques (fibrosis of the parietal pleura), (3) diffuse pleural fibrosis (typically 
affects visceral pleura which can extend to parietal), and (4) rounded atelectasis (an area 
of visceral pleural fibrosis extending to the parenchyma rendering the underlying lung 
tissue airless) (American Thoracic Society, 2004; Cugell & Kamp, 2004; Chapman et al., 
2003). The primary malignancy of the pleura is mesothelioma (Cugell, 2004). The 
parenchymal consequences of asbestos exposure are asbestosis (fibrosis of the pulmonary 
interstitium) and bronchogenic lung cancer (American Thoracic Society, 2004; Cugell & 
Kamp, 2004).    
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2.8.1 Pleural Consequences of Asbestos Exposure 
Brief explanations of the benign pleural consequences of asbestos exposure are 
described below. The four types of benign asbestos-related pleural disease are important 
because they are common in asbestos-exposed workers and may result in abnormal lung 
function and symptoms.   
2.8.1.1 Pleural Effusion 
Benign pleural effusion attributed to asbestos-exposure is an early manifestation 
of pleural asbestos disease and usually appears within twenty years of first exposure 
(American Thoracic Society, 2004; The Spanish Society of Pulmonology, 2005; 
Chapman, Cookson, Musk, & Lee, 2003). The latency period can be as short as ten years 
(American Thoracic Society, 2004; The Spanish Society of Pulmonology, 2005). The 
exact prevalence of pleural effusions is unknown because many cases are subclinical, but 
could be estimated in a population screening study using computed tomography, the most 
sensitive imaging modality for visualizing pleural fluid (Cugell, 2004; Roach, Davies, 
Attanoos, Crane, Adam, & Phillips, 2002).  Pleural effusions, accumulation of fluid in the 
pleural cavity, are exudative and often hemorrhagic with mixed cellularity and usually do 
not contain asbestos bodies (Roach et al., 2002).  
The presentation can vary from completely asymptomatic with total resolution, to 
an active, inflammatory pleuritis with pain, fever, and dyspnea (American Thoracic 
Society, 2004; The Spanish Society of Pulmonology, 2005, Chapman et al., 2003). The 
symptoms of asbestos-related pleural effusion do not differ from other forms of acute 
pleuritis and therefore can only be attributed to asbestos after two to three years of 
observation, when there is a history of asbestos exposure and all other causes, particularly 
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malignancy, have been excluded (Cugell & Kamp, 2004).  Asbestos pleural effusions 
have no prognostic implications with respect to subsequent development of other 
asbestos pleural diseases or pulmonary functional complications.  
 
2.8.1.2 Pleural Plaques 
Pleural plaques are circumscribed and discrete areas of hyaline or calcified 
fibrosis, which are localized on the parietal pleura of the lateral chest wall, the 
diaphragm, or the mediastinum (Chapman et al., 2003; Genenois, de Maertelaer, & 
Madani, 1998). They are clearly the most common manifestation of the inhalation, 
retention and biologic effect of asbestos (American Thoracic Society, 2004). Their 
prevalence is most directly related to time since first exposure and they rarely occur 
within less than 20 years of first exposure (American Thoracic Society, 2004). Pleural 
plaques consistent with asbestos exposure appear in the chest radiography of 2.3% of U.S 
males (Rogan, Gladen, Ragan, & Anderson, 1987).  Approximately 85% of heavily 
exposed asbestos workers showed pleural plaques on chest radiography with more than 
40 years since first exposure (Sison, Hruban, Moore, Kuhlman, Wheeler, & Hutchins, 
1989).  
Assessments of pulmonary function of patients with pleural plaques has yielded 
conflicting results, with studies complicated by variations in degrees of exposure, the 
presence of other asbestos-related diseases, and confounding factors such as smoking.  
Some studies have demonstrated no significant association between pleural plaques and 
abnormal lung function (Oliver, Eisen, Green, & Sprince, 1988; Ohlson, Rydman, 
Sundell, Bodin, & Hogstedet, 1984).  
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This led to the notion that pleural plaques were inconsequential markers of 
asbestos exposure; however several large cohort studies have shown a significant 
reduction in lung function attributable to plaques.  Taking into account the degree of 
interstitial fibrosis, smoking and duration of asbestos exposure, pleural plaques were 
associated with decreased vital capacity. (Schwartz, Fuortes, Galvin, Burmeister, 
Schmidt, Leistikow, LaMarte, & Merchant, 1990). This has not been a consistent finding, 
and is possibly related to early subclinical fibrosis not detectable by plain chest 
radiograph, or residual confounding (Schwartz et al., 1990). 
 
2.8.1.3 Diffuse Pleural Thickening  
Diffuse pleural thickening is extensive fibrosis of the visceral pleura with areas of 
adhesion to the parietal pleura, and ill-defined margins often involving the costophrenic 
angles, apices and interlobular fissures (American Thoracic Society, 2004; Chapman et 
al., 2003).  Diffuse pleural thickening, unlike circumscribed pleural plaques can cause 
significant restrictive pulmonary function impairment, especially with blunting of the 
costophrenic angle (Cugell & Kamp, 2004). A reduction of 270 ml of FVC has been 
associated with diffuse pleural thickening (Schwartz et al., 1990; Kee, Gamsu, & Blanc, 
1996).  Workers with diffuse pleural thickening have a significantly greater decrease in 
FVC (two times) compared to those with circumscribed pleural plaques (Schwartz et al., 
1990). Copley et al. found an inverse relationship with FVC and diffuse pleural 
thickening along with a reduction in carbon monoxide diffusing capacity, suggesting that 
reductions in lung volumes was not solely due to pleural fibrosis but also parenchymal 
fibrosis (Copley et al., 2001). 
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2.8.1.4 Rounded Atelectasis  
Rounded atelectasis (RA), also known as shrinking pleuritis, folded lung, or 
Blesovsky syndrome, is the least common of all benign asbestos-induced pleural and 
parenchymal changes (Cugell & Kamp, 2004; Stathopoulos, Karamessini, Sotiriadi, & 
Pastromas, 2005). RA is found in areas adjacent to pleural fibrosis and consists of 
collapsed pulmonary parenchyma surrounded by thickened and invaginated pleura 
(Stathopoulos et al., 2005; Terra-Filho, Kavakama, Bagatin, Capelozzi, Nery, & Tavares, 
2003). RA appears on CT-scans as a rounded peripheral mass abutting thickened pleura 
with a diameter between 3.5-7-cm (Cugell & Kamp, 2004). The classic “comet tail” is 
pathognomonic and is more readily seen on high resolution computed tomography 
(HRCT) than on plain chest radiographs (American Thoracic Society, 2004).  A solitary 
RA causes no significant functional impairment unless it is accompanied by other pleural 
of parenchymal sequelae of asbestos exposure, especially diffuse pleural thickening (Kee 
et al., 1996).  
 
2.8.2 Benign Parenchymal Consequences of Asbestos Exposure 
2.8.2.1 Asbestosis 
The development of diffuse interstitial pulmonary fibrosis due to inhalation of 
asbestos fibers is known as asbestosis (American Thoracic Society, 2004; The Spanish 
Society of Pulmonology, 2005; Cugell & Kamp, 2004). A latency period of 15 and 20 
years between first exposure and appearance of fibrosis has been estimated; however no 
consensus has been reached on the subject (The Spanish Society of Pulmonology, 2005). 
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The most common clinical symptom of asbestosis is dyspnea on exertion which becomes 
progressively more severe and present at rest (Copley et al., 2001). Over time this will 
lead to restrictive impairment and decreased diffusing capacity characterized by a 
reduction in FVC, TLC and DLCO (American Thoracic Society, 2004; Manning et al., 
2002; Ross, 2003).  
Though the classic finding in asbestosis is a restrictive impairment, mixed 
restrictive and obstructive impairments are frequently seen. However, isolated obstructive 
impairment is rare and unusual (American Thoracic Society, 2004). Low diffusing 
capacity for carbon monoxide has been reported as the most sensitive indicator of early 
asbestosis, though the finding is also relatively non-specific (The Spanish Society of 
Pulmonology, 2005).  This is because diffuse interstitial pulmonary fibrosis first and most 
extensively affects the smallest airways, alveolar ducts, alveoli and microcirculation 
where gas exchange occurs (Ross, 2003).   However many additional factors can lead to a 
low DLCO therefore it is not highly specific for asbestosis (Ross, 2003).  
 
2.9 Distinguishing Between Pleural and Parenchymal Asbestos Disease 
The diagnosis of asbestosis has important medicolegal implications and the 
distinction between asbestos-related parenchymal and pleural disease is important as the 
magnitude of compensation may be much greater with asbestos-induced interstitial 
fibrosis (Copley et al., 2001).  Pleural changes are often present in cases of asbestosis.  It 
has been reported that 80% of patients with asbestosis have coexistent pleural disease at 
chest radiography (Dee, 2000) and the percentage rises to 100% with the use of high-
resolution CT (Aberle, Gamsu, Ray & Fauerstein, 1988). Parenchymal bands are defined 
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as linear opacities, several millimeters wide and up to 5-cm long which extend to the 
pleura (Peacock, Copley, & Hansell, 2000; Genenois et al., 1998). This feature is due to 
adjacent visceral pleural thickening and is not regarded as a defining feature of asbestosis 
(Genenois et al., 1998). Because pleural disease can cause distortion of adjacent lung 
parenchyma, parenchymal features in areas unrelated to pleural disease are more 
diagnostically convincing for asbestosis (Genenois et al., 1998; Kipen, Lilis, & Suzuki, 
1987).     
2.10 Imaging of Asbestos-Exposed Individuals    
 Imaging has several implications in the evaluation of asbestos-related disease: in 
diagnosis, for the quantification of disease extent, as part of medicolegal claims evidence, 
to potentially screen high-risk individuals for cancer and for distinguishing other (non 
asbestos-related) causes of pulmonary disability.   
2.10.1 Chest Radiography 
Imaging findings are pivotal in the diagnosis of asbestos-related diseases. The 
American Thoracic Society (ATS) guidelines published in 2004 advocated caution in 
diagnosing asbestosis if radiographic changes were not present.  
 Since 1980 the International Labor Organization (ILO) Classification of 
Radiographs for the Pneumoconioses has been the gold standard for recording chest 
radiographic abnormalities of the lung and pleura related to asbestos exposure 
(International Labour Office, 2000; Huuskonen, Kivisaari, Zitting, Taskinen, 
Tossavainen, & Vehmas, 2001).  The purpose was to improve workers’ health 
surveillance by facilitating international epidemiologic comparisons through coding of 
radiographic abnormalities in a simple reproducible manner by means of comparison 
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with a standard set of radiographs to reduce inter-observer variability (Roach et al., 
2002).  In contrast to most tests, it was designed primarily for population epidemiology 
rather than individual diagnoses. The system describes changes on a posteroanterior chest 
radiograph.  Small opacities, which may differ in shape, size and profusion, are seen in 
early disease and are denoted by the symbols s, t, and u for irregular opacities, and p, q 
and r for rounded or nodular opacities (International Labour Office, 2000).  Large 
opacities are those greater than 1-cm in diameter and are graded A, B or C based on the 
combined dimensions of all large opacities present (Roach et al., 2002).  Profusion of the 
small opacities is classified into four categories (0 – 3) in comparison to the standard 
films, category 0 being no excess of small opacities above normal.  For example, 1/0 
indicates the appearance most closely resembles category 1 but the reader has also 
considered category 0 (International Labour Office, 2000).   
The initial radiographic presentation of asbestosis is ground-glass opacification 
and bilateral, small, irregular parenchymal opacities in the lower lobes (American 
Thoracic Society, 2004).  In more advanced stages of the disease the fine reticular pattern 
becomes coarser and results in honeycombing (Roach et al., 2002).  However, 
honeycombing is only present in 7 – 17 % of cases (Aberle et al., 1998). If 
radiographically found fibrosis is predominantly in the upper or mid zone distribution, 
asbestosis is less likely than other causes (American Thoracic Society, 2004).  Though 
asbestosis characteristically appears earliest in the lower lung lobes, there is a rare but 
well-characterized syndrome of massive bilateral upper lobe fibrosis, in the absence of 
tuberculosis or lung cancer (Hillerdal, 1990).  
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A disadvantage of the chest radiograph is that the radiograph may be normal in 
individuals with asbestosis (Kipen et al., 1987).  Although chest radiograph findings are 
usually abnormal in patients with asbestosis, approximately 10-15% appear normal, 
yielding a sensitivity of 85-90% (Friedman, Fiel, Fisher, Radecki, Lev-Toaff, & Caroline, 
1988). Furthermore, many factors other than asbestos exposure can lead to a mildly 
abnormal chest radiograph finding, affecting specificity.  Such factors are differing 
radiographic technique, aging, obesity, smoking, presence of chronic obstructive 
pulmonary disease, and exposure to other fibrogenic and non-fibrogenic dusts (American 
Thoracic Society, 2004; Roach et al., 2002).  Lastly, the chest radiograph and the 
International Labor Organization (ILO) system have significant inter- and intraobserver 
variability for both pleural and parenchymal diseases (Bourbeau & Ernst, 1988).   
Chest radiography remains an important epidemiological and diagnostic tool 
because of limited access to CT and because it is relatively specific in individuals with 
advanced parenchymal disease and appropriate asbestos exposure history.  However, in 
individuals with early parenchymal changes due to asbestos-exposure and extensive 
pleural disease which obscures the lung parenchyma, the need for thin-section CT is 
evident.  
 
2.10.2 Computed Tomography  
Several studies and most recently the 2004 ATS guidelines recognize computed 
tomography (CT) as having increased sensitivity, greater inter-observer agreement and 
more diagnostic accuracy for structural pulmonary change (American Thoracic Society, 
2004; Grenier, Valeyre, & Cluzel, 1991; Mathieson, Mayo, & Staples, 1989).  The ATS 
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guidelines recommend that CT sections should be obtained with at least 2-mm intervals 
for the most accurate assessment of pleuropulmonary abnormalities (American Thoracic 
Society, 2004).  However, early studies demonstrated that even conventional thick slice 
CT was more sensitive for diffuse pleural thickening and early asbestosis than chest 
radiography due to the lack of superimposed structures (Katz & Kreel, 1979).   
There are several high-resolution (HR)-CT features of asbestosis which have been 
extensively described. In early disease, subpleural branching is seen.  As the disease 
becomes more advanced the subpleural branching becomes more confluent producing 
pleural based nodular irregularities.  Other features of fibrosis on CT scans include 
subpleural curvilinear areas (linear densities usually within 1-cm of the pleura and 
parallel to the chest wall), ground glass opacity (increased attenuation of the lung without 
obstruction of the underlying bronchovascular margins), parenchymal bands (linear non-
tapering densities 2-5 cm in length, extending through the lung to contact the pleural 
surface), thickened interlobular (septal) and intralobular (core) lines (when numerous 
appear as fine reticular pattern), and later honeycombing (cystic air spaces with well-
defined walls) (Gamsu, Salmon, Warnock, & Blanc, 1995; Lynch, Gamsu, & Aberle, 
1989).  
Subpleural curvilinear lines which represent fibrosing bronchioloalveolitis was 
initially thought be to characteristic of asbestosis (Yoshimura, Hatakeyama, & Otsuji, 
1986), however after being found in patients without asbestos exposure is no longer 
thought to be pathognomonic.  
Gamsu et al. found the most common HR-CT abnormalities of asbestosis were 
interstitial lines (defined as thickened interlobular septa and centrilobular core structures), 
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which were found in 84% of cases (Gamsu et al., 1995).  This was followed by 
parenchymal bands in 76% of cases and distortion of secondary pulmonary lobules (56% 
of cases).  Features such as subpleural lines and honeycombing were less frequent.   
However, all of the above listed CT features are non-specific, since they can also 
be observed in pulmonary fibrosis from other causes, especially idiopathic pulmonary 
fibrosis (IPF) (Lynch et al., 1989).  Asbestosis is not characterized by an individual CT 
feature, rather a constellation of the features listed above which are bilateral and 
multifocal with a coexisting occupational history (Gamsu et al., 1995). Often the 
presence or absence of pleural plaques or diffuse pleural thickening and/or coexisting 
appropriate occupational history is relied on to discriminate between asbestosis and IPF. 
Differences in prognosis and eligibility for compensation highlight the need for accurate 
differentiation.  The lack of a standardized interpretation of CT, such as the ILO for chest 
radiographs is a limitation for using CT in the diagnosis of asbestos-related diseases.  
Despite an absence of an internationally accepted classification tool for asbestosis 
determined by CT, Huuskonen et al. recorded several specific HR-CT parenchymal 
abnormalities and found good inter- and intraobserver agreement.  The parenchymal 
abnormalities were: (i) subpleural dependent opacity, (ii) subpleural curvilinear opacities, 
(iii) subpleural perpendicular lines (septal lines), (iv) parenchymal bands, (v) small 
irregular parenchymal opacities, and (vi) honeycombing.  The severity of each 
abnormality was recorded from mild to profuse. Receiver-operating characteristic (ROC) 
area under the curve was significantly greater for HR-CT fibrosis score (0.89) than for 
the ILO radiographic classification (0.76) (P<0.0001) (Huuskonen et al., 2001). It has 
been suggested that this type of semi-quantitative HRCT scoring system could be of use 
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when an international HR-CT classification is designed for occupational lung disease 
(American Thoracic Society, 2004).  
 Multidetector CT (MDCT) is the newest design of CT technology which differs 
from its predecessors in the design of the detector array.  By replacing a single detector 
row by 4-, 6- or 64- detector rows, the simultaneous collection of data from different slice 
locations can occur during a single rotation of the x-ray source. This allows for rapid 
scanning and anatomic coverage.  The raw data can then be reconstructed to provide thin 
1.25-mm and 5-mm sections (Prokop, 2003).  Therefore a single scan by the MDCT can 
be given to patients who potentially have combined focal and diffuse lung disease.  This 
also provides the opportunity to screen individuals at high risk for lung cancer or 
mesothelioma due to smoking or asbestos-exposure while evaluating potential asbestosis.    
 The International Commission of Radiological Protection has suggested the 
principle of ALARA (as low as reasonably achievable). This concept has become more 
relevant with the growing use of CT for diagnostic, interventional and screening purposes 
(Zhu, Yu, & Huang, 2004).  The low-dose CT has been primarily used for lung cancer 
screening studies and in pediatric patients because of the potential risk associated with 
repeated annual screening (Roberts, Patsios, Paul, McGregor, Weisbrod, Chung, Herman, 
Boerner, Waddell, Keshavjee, Darling, Pereira, Kale, Bayanati, Sitartchouk, Tsao, & 
Shepard, 2007; Zhu et al., 2004).  Radiation dose is proportional to the tube current at a 
fixed voltage, scanning time, and slice width therefore lowering tube current or X-ray 
flux can lower radiation dose received by patients.  A milliampere-second (mAs) 
corresponds to the rate at which electrons leave the cathode in the X-rate tube and is 
directly proportional to the radiation dose. Therefore a reduced mAs is a practical means 
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of lowering radiation dosage.  There has been investigation of optimal low-dose imaging 
protocols which results in a minimal reduction in image quality. A study by Zhu et al. 
attempted to minimize patient exposure to ionizing radiation from MDCT scans while 
maintaining sufficient image quality to detect pulmonary diseases (Zhu et al., 2004).  A 
low-dose (40 or 25 mA) MDCT produced satisfactory image quality while maximally 
protecting patients from radiation exposure.    
The combination of MDCT and low-dose techniques stimulated interest in using 
CT as a first-line imaging modality for the diagnosis of asbestos-related disease.  A study 
comparing the use of low dose multidetector helical CT with contiguous 5-mm 
reconstructions as opposed to thin interspaced sections for the detection of asbestos-
related pleura-parenchymal disease found no apparent loss of diagnostic accuracy (Remy-
Jardin, Sobaszek, Duhamel, Mastora, Zanetti, & Remy, 2004).  The study included 
eighty-three male workers with a mean duration of occupational exposure to asbestos of 
eighteen years who underwent CT as part of a medicolegal investigation. Interpretations 
of the low-dose and thin-section CT images were interpreted several weeks apart by two 
radiologists simultaneously.  Two main groups of abnormalities were assessed: (a) 
pleural abnormalities including pleural plaques and diffuse pleural thickening, and (b) CT 
features of asbestosis which included four major abnormalities, thickened interstitial 
short lines, curvilinear subpleural lines, ground glass opacities, and honeycombing.  The 
only significant difference observed was the depiction of fissural pleural plaques, which 
were seen more frequently in low-dose CT images.  There was no significant difference 
in the depiction of CT features compatible with the presence of lung parenchymal 
asbestosis (Remy-Jardin et al., 2004).  
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2.11 Radiological-Functional Correlation  
The traditional radiological evaluation in asbestos-exposed individuals has 
historically been chest radiography and various studies have correlated radiographic 
features with physiological indices such as exercise data and pulmonary function tests, 
with conflicting results (Becklake, Fournier-Massey, & McDonald, 1970; Lee, Singh, & 
Pang, 2003; Miller, Lilis, & Godbold, 1992; Wang, Yano, Wang, Wang & Christiani, 
2006; Ohar, Sterling, Bleecker, & Donohue, 2004; Kilburn & Warshaw, 1994).  Although 
abnormal pulmonary function induced by exposure to asbestos is thought to be 
characterized by a restrictive pattern, and reduced lung volumes and gas transfer, it has 
remained a controversial issue whether asbestos exposure is also associated with 
substantial airway obstruction.  Several studies have suggested an association between 
asbestos and airway obstruction (Begin, Cantin, Berthiaume, Boileau, Peloquin, & 
Masse, 1983; Kilburn & Warshaw, 1994; Ohar et al., 2004) while others did not (Alfonso 
et al., 2004; Wang et al., 2006).  This discrepancy between studies may be due to 
variations in occupational conditions, exposure intensity, smoking habits or other 
differences in the selected study subjects.  Another reason for the inconsistency between 
studies may be due to different analytic methods.   
Ohar et al. attempted to assess patterns of asbestos-induced lung disease from the 
Selikoff Registry.  A total of 3383 asbestos-exposed workers were referred for 
independent medical evaluation and received a chest radiograph, pulmonary function test, 
and an extensive questionnaire.  Entry criteria for a medical evaluation included 
documented workplace asbestos exposure, a latency of greater than ten years since 
exposure, and an abnormal chest radiography pattern consistent with asbestos exposure.  
In a regression model, latency corrected for age, percentage of predicted FEV1 and 
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smoking history in pack-years predicted ILO score, but not FEV1/FVC or percentage of 
predicted FVC. When patients were classified according to disease state, restrictive 
pulmonary function was found mainly in subjects with mesothelioma, and an obstructive 
pattern was the major finding in subjects with bronchogenic cancer and subjects with 
both high and low ILO scores.  In this study the mean latency of subjects was 41.4 
(SD=10.1) years, the mean age was 65.1 (SD=9.9) years, and the frequency of current 
smokers was 19%.  The conclusion that asbestos-induced lung disease is characterized by 
normal or obstructive pulmonary function abnormalities was based on descriptive 
statistics, as regression results were not done, and therefore may not be appropriate (Ohar 
et al., 2004).   
Several studies have also shown that asbestos is not involved in the development 
of obstructive lung disease.  Alfonso et al. conducted a prospective cohort of former 
workers of Western Australia, a unique well documented cohort which has been almost 
exclusively exposed to documented levels of crocidolite asbestos (Alfonso et al., 2004). 
Cumulative exposure was determined by the product of estimated or measured fiber 
concentration and the length of time at the job, for each job.  Each subject had a plain 
chest radiograph classified according to ILO criteria at study entry and at least one 
spirometric test.  The data was modeled by general linear mixed effects model. To assess 
the effects of asbestos exposure and tobacco smoking on the levels and rates of decline of 
lung function, the dependent variables (FEV1, FVC and FEV1/FVC) were regressed on 
time controlled for sex, age and height.  The study found that higher cumulative exposure 
to asbestos or subjects with radiographic asbestosis had significantly lower levels of 
FEV1 and FVC.  FEV1/FVC was not associated with asbestosis.  These findings suggest 
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asbestosis is associated with restrictive respiratory defect, not obstructive.  The study also 
found no significant interaction of smoking status on the relationship between asbestos 
exposure and lung function.  Wang et al. conducted a cross-sectional study involving 468 
chrysotile asbestos workers in Chongqing, China, and 282 electronic equipment 
manufacturing workers as a control group.  Occupational history ascertained from face-
to-face interview and factory records determined cumulative exposure year as a surrogate 
of personal exposure level since data on individual exposure levels was not available.  
Posteroanterior chest radiograph was used to diagnose asbestosis.  Multivariate 
regression analysis indicated that exposure to asbestos was significantly associated with 
decreased FVC and DLCO.  Radiographic asbestosis was strongly associated with a 
decreased FVC, and elevated FEV1/FVC.  There were no significant interactions 
observed (Wang et al., 2006).   
The aforementioned studies among others used chest radiography to ascertain 
morphological changes due to asbestos exposure.   However, chest radiography has been 
shown to be an insensitive means of correlating morphology with pulmonary function in 
other causes of diffuse interstitial lung disease (Carrington, 1976; Gaensler, Carrington, 
& Coutu, 1972).  According to the American Thoracic Society CT-scan is now without 
contest the reference tool for diagnosis of asbestos-related diseases as this technique is 
both more sensitive and specific than radiographic systems based on the ILO 
classification system (American Thoracic Society, 2004). An international consensus 
conference has recommended the use of CT-scan in exposed populations for clinical 
individual evaluation or research purposes with respect to pleura plaques and asbestosis 
(Consensus Report, 1997).   
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In addition, individuals with asbestosis may have other co-existing 
histopathological processes also contributing to functional deficits, such as emphysema, 
small airways disease or diffuse pleural thickening.  Cigarette smoking is common 
among workers exposed to asbestos, and emphysema frequently complicates the 
interpretation of physiologic impairment in patients with asbestosis (Copley et al., 2007). 
It has been suggested that concurrent emphysema with interstitial lung disease may be 
impossible to properly detect radiographically, therefore it is a major confounder of 
previous pulmonary function indices, with a paradoxical preservation of lung volumes 
and disproportionate reduction in DLCO (Wells, King, & Rubens, 1997). Also, additional 
conditions may be distributed separately from the predominantly lower zone interstitial 
fibrosis, such as upper zone centrilobular emphysema.  Therefore CT may give a more 
detailed description of the relative proportions of morphologic changes in the lungs and 
pleura such as interstitial fibrosis, emphysema, and diffuse pleural thickening.  In 
asbestos-exposed individuals, the definition of the functional consequences of asbestos, 
as opposed to those caused by smoking, has significant medicolegal implications because 
emphysema is not generally compensatable (Copley et al., 2007).  
Accordingly it became of interest to know whether this higher sensitivity of thin-
section CT, as compared to conventional radiography, would translate into an enhanced 
prediction of physiologic parameters.  Several studies have correlated physiological 
indices with CT morphology in asbestos-exposed individuals (Aberle, Gamsu, & Ray, 
1988; Staples, Gamsu, & Ray, 1988; Neri et al., 1996; Sette et al., 2004).  The first group 
to correlate thin-section CT morphology with lung function in asbestos-exposed 
individuals was Aberle et al. in 1988. They found significant inverse correlations between 
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probability scores for asbestosis and percent predicted FVC and single-breath diffusing 
capacity (Aberle et al., 1988).  The probability scores were derived from the 
combinations of thin-section CT features such as parenchymal bands, interstitial 
thickening and honeycombing.  The study did have several limitations in that no attempt 
to correlate CT-found pleural disease with pulmonary function. No attempt was made to 
identify the presence of emphysema.   
Staples et al. attempted to correlate HRCT findings with lung function in their 
study of asbestos workers with normal chest radiograph.  When comparing asbestos-
exposed workers with a normal or near-normal HRCT to workers with abnormal and 
suggestive for asbestosis HRCT the groups did not differ significantly in their duration of 
asbestos exposure, latency, smoking history, or measures of airflow obstruction (FEV1%, 
FEV1/FVC).  The subjects with parenchymal abnormalities did show significantly 
different values of FVC% (-7.2) and DLCO% (-8.9) in comparison to subjects with 
apparently normal parenchyma suggesting reduced lung function indicative of restrictive 
lung disease.  This work investigated the prevalence of lesions related to asbestos-
exposure in persons already affected with clinical symptoms or for whom a suspicion of 
asbestosis had already been formulated (Staples et al., 1988).  Neri et al. evaluated the 
presence of asbestos-related pleural and parenchymal abnormalities in asymptomatic 
workers with normal chest radiographs and their correlation with pulmonary function and 
smoking habits (Neri et al., 1996). Asbestos-exposed asymptomatic workers received a 
HRCT scan, CO-diffusing capacity, pulmonary function tests and face-to-face interviews 
to determine occupational, smoking and health history.  There was no non-asbestos 
exposed control group. The study found that early parenchymal abnormalities found by 
	  
	  
43	  
	  
HRCT were correlated with function impairment.  HRCT parenchymal abnormalities 
were associated with decreased FVC in nonsmoking asbestos workers, and with a 
reduction in obstructive indices among smoking colleagues, without any clinical evidence 
of disease (Neri et al., 1996).  The interaction between packs/years smoked and duration 
of asbestos exposure was not significant.  This study also failed to account for co-existing 
conditions, particularly emphysema.   
Sette et al. (2004) explored the relationship between thin-section CT interstitial 
abnormalities and indices of pulmonary gas exchange impairment at rest and during 
moderate exercise in workers exposed to asbestos, using a scoring system based on a 
combination of semi-quantitative and severity score and a qualitative score based on 
individual CT features (Sette et al., 2004).  Using this system to classify CT findings, CT 
was found to be useful in assessing the likelihood of gas exchange impairment at rest and 
during exercise.  Specifically, the results of the logistic regression analysis, which was 
used to consider all abnormalities, including pleural plaques, indicated that only 
parenchymal bands and subpleural nodules were significantly associated with impairment 
in gas exchange.  However, once again the effects of coexisting diffuse pleural thickening 
and emphysema were not evaluated.  Also notable is that there was no association 
between CT abnormalities and any clinical variables including smoking history, years of 
asbestos exposure or individual spirometric values such as FEV1 or FVC (Sette et al., 
2004).   
Most recently, Copley et al. (2007) retrospectively correlated the extent of 
individual disease seen at thin-section CT with pulmonary function in a group of patients 
with asbestos-related parenchymal disease (asbestosis) (Copley et al., 2007). The results 
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demonstrated that CT substantially increased the precision with which the results of 
pulmonary function tests can be interpreted in patients exposed to asbestos.  By using 
multiple regression analysis, Copley et al. identified a combination of CT features most 
closely linked to individual pulmonary function indexes. Thus, for a given reduction in 
TLC or DLCO, the proportion of pulmonary deficit that can be ascribed to fibrosis, 
diffuse pleural thickening and emphysema could be preliminarily estimated.  The derived 
multiple regression analyses were validated by their accurate prediction of pulmonary 
function indexes in a subsequent study group.  
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2.12 Research Questions 
  
The previous literature review suggests several study questions.  We evaluated the 
following questions in a cohort of asbestos-exposed workers from the Sarnia, Ontario, 
Canada:  
 
1) What is the prevalence of pulmonary fibrosis in a well described asbestos-
exposed cohort of workers in Sarnia, Ontario, Canada as determined by low-dose 
computed tomography? 
 
2) To develop a predictive model which assesses multiple predictors of pulmonary 
fibrosis found by low-dose CT, specifically past asbestos exposure, pulmonary 
function indices (FVC, FEV1, FEV1/FVC, TLC, and DLCO) and smoking. 
 
3) Based on this model, is there an interaction between asbestos exposure and 
smoking that affects  risk of pulmonary fibrosis? 
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Figure  6: Graph of Planned Associations to be Addressed Displaying Potential Predictors 
of Pulmonary Fibrosis Found by Low-Dose CT of Interest to Hypothesis Testing and 
Model Adjustment  
*COPD= Chronic Obstructive Pulmonary Disease 
** Found by low dose computed tomography at baseline scan 
COPD** 
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CHAPTER III- METHODS 
 
3.1 Introduction 
 This chapter describes the study design and methods. The methods of patient 
recruitment and consent, data collection, imaging techniques, and specific measurements 
are outlined.  The chapter concludes with a description of the analytic strategies that will 
be used within the study to address the specific research questions presented in the 
previous chapter 2.   
3.2 Study Design and Context 
 The current project is an ancillary study attached to a longitudinal occupational 
cohort that is being conducted at Princess Margaret Hospital.  The study is led by 
researchers at the Toronto University Health Network, and the Occupational Health 
Clinic for Ontario Workers (OHCOW) in Sarnia-Lambton, Ontario.  The cohort is the 
Early Diagnosis of Mesothelioma and Lung Cancer in Prior Asbestos Workers.  The 
original study was designed to evaluate lung cancer and mesothelioma at an early stage 
by screening high-risk individuals, defined by their prior occupational asbestos exposure 
and/or presence of pleural plaques, with low-dose computed tomography.   
3.3 Patient Recruitment 
Patient accrual began in March, 2005 and is still in progress.  For the purpose of 
this study, data collected between March, 2005 and November, 2008 are used.  The 
majority of patients have been referred to the study from the Sarnia-Lambton, OHCOW.  
Sarnia-Lambton is situated along the St. Clair River and contains a large petrochemical 
complex, which produces approximately 40% of Canada’s chemicals, using companies 
such as Imperial, Dow, Bayer, Shell and Suncor (Brophy et al., 2007).  The majority of 
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the chemical industries in Sarnia-Lambton have a history of extensive asbestos use.  
Consequently, many workers in Sarnia-Lambton are at elevated-risk for developing 
asbestos-related diseases.   
3.4 Eligibility Criteria  
To be eligible for entrance into the original study subjects were required to meet the 
following criteria:  
1) > 30 years of age 
2) Asbestos exposure at least 20 years ago and/or documented pleural plaques 
3) Presumable good health 
4) Have no prior cancer (with the exception of non-melanotic skin cancer) 
3.5 Measurements 
3.5.1 Consent and Data Collection 
Eligible individuals were asked to read a consent form and sign it.  Once consent 
was obtained individuals were administered a questionnaire in a face-to-face interview 
with the clinical research coordinator or clinical research assistant.  Appended is a copy 
of the consent form and questionnaire.  The questionnaire includes questions regarding 
patient address, contact information, date of birth, date of entry to study, occupational 
history, medical history and smoking habits.   
3.5.2 Occupational History 
 The baseline questionnaire included detailed questions regarding occupational 
history. Questions included:  
- Name of employer  
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- Occupation (construction, ship construction, mining, building maintenance, 
demolition, repair, chemical industry, other)  
- Start and end year of exposure (and corresponding age) 
- How often was the exposure? (everyday, once a month, once a week, other) 
- Did you work directly with asbestos? (If yes, describe your activities i.e. spraying, 
applying, cutting, removing) 
- Which type of asbestos were you in contact with? (serpentine/ chrysotile/white, 
amphiboles/brown/off-white, crocidolite/blue, unknown) 
- Did you wear any personal protective equipment?    
- Did you work in areas where other workers were generating asbestos dust? 
(indirect exposure)  
3.5.3 Smoking History Assessment and Other Measurements 
 Smoking history was obtained from the face-to-face questionnaire.  Information 
on smoking status (never smoker, former smoker, current smoker), type of tobacco 
used/smoked (cigarettes, marijuana, cigars, pipes, smokeless tobacco), age when smoking 
cigarettes began, packs of cigarettes smoked per day (for current and formers smokers) 
and how many years did you smoke this amount of packs per day, were obtained.   
 Other data collected were sex, race, height (self-reported), weight (self-reported), 
has a  health professional ever told that he/she had any of these medical conditions 
(asthma, asbestosis, pleural plaques, emphysema, chronic bronchitis, hypertension, heart 
attack, stroke, heart failure, liver disease, renal disease, connective tissue disease, other), 
respiratory symptoms in the past year, family history (lung disease, asbestosis, 
mesothelioma), and general health.  
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3.6 Low-Dose Computed Tomography and Follow-up 
  The baseline CT scan consists of a low-dose, thin-slice acquisition, which is 
performed on one of the several scanners within the Department of Medical Imaging at 
University Health Network, acquired from various manufacturers (General Electric 
Medical System, Toshiba Medical Systems, and Siemens Medical Solutions) and having 
different numbers of channels (4 to 64)  all using a low-dose regimen (40 to 60 mA, 120 
kV, 1 to 1.25-mm axial reconstructions).  
 All participants were given a low-dose CT (LDCT) examination of the entire 
thorax.  The results from the CT scan were summarized into a Research CT Evaluation 
Report (Appendix C) by the study radiologists.  The report includes descriptions of 
nodules, plaques, asbestos-related findings and other chest abnormalities.  The Research 
CT Evaluation Report was abstracted for information regarding date of scan, presence of 
chronic obstructive pulmonary disorder (emphysema, chronic bronchitis, and 
bronchiectasis), atelectasis (non-obstructive, round) and fibrosis of the lung parenchyma. 
All of the above abnormalities were coded as 0=not present, 1=mild, 2=moderate, 
3=severe, and 8=present with severity not marked.  As noted previously, there have been 
attempts to describe several specific CT parenchymal abnormalities of asbestosis 
including (i) subpleural dependent opacity, (ii) subpleural curvilinear opacities, (iii) 
subpleural perpendicular lines (septal lines), (iv) parenchymal bands, (v) small irregular 
parenchymal opacities, and (vi) honeycombing (Huuskonen et al., 2001). These CT scan 
found abnormalities had a ROC-AUC of 0.89 and performed better in classification of 
pulmonary fibrosis than ILO radiographic classification (ROC-AUC=0.76). However, the 
primary goal of the Early Diagnosis of Mesothelioma and Lung Cancer in Prior Asbestos 
Workers was not for classification of pulmonary fibrosis, therefore an in-depth 
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classification was not performed. Pulmonary fibrosis will be examined dichotomously, 
present or absent as noted by the study radiologist.  The study radiologist took into 
consideration to following CT features when classifying a person as having pulmonary 
fibrosis: subpleural curvilinear lines, interlobular septa thickening, intra-(core lines), 
subpleural ground glass opacity, honeycombing, and parenchyma bands.  
Structural findings from the baseline low-dose CT scan determines the time of 
follow-up CT scan. Figure 7 graphically depicts the follow-up algorithm.  All participants 
received an annual follow-up scan. Other possible follow-up dates are 3or 6 month as 
well as 3 month post-annual, and biennial. 
 
	  
 
 
 
 
 
 
 
 
 
Figure 7: Low-dose Computed Tomography Follow-Up Scheme 
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3.7 Pulmonary Function Tests 
 The hardcopy medical records of subjects were abstracted at Toronto General 
Hospital to obtain all pulmonary function tests which had been performed. Variables 
abstracted include date of PFT, spirometry measures (FVC, FEV1, and FEV1/FVC), 
measurements of lung volume (TLC) and diffusion capacity for carbon monoxide 
(DLCO, DLCO/VA). These functional variables are expressed as absolute liters (L) and 
as a percentage of the predicted value (%) according to a course of reference values based 
on healthy volunteer data and which are matched to the patient’s age, height, sex, and 
race.  The timing of PFTs in relation to date of the LDCT varied for subjects, but in the 
current dataset only PFTs that preceded the LDCT were included. 
 
Table 3: Pulmonary Function Test Variables in Relation to Different Types of Lung 
Impairment 
Variable  Pre or Post 
Bronchodilator 
Unit Lung Impairment Measure and 
Important Notes   
Forced Vital 
Capacity (FVC) 
Pre and post Absolute Liters (L) 
and percentage of 
predicted (%)  
Decreased in restrictive lung 
impairment 
Forced Expiratory 
Volume in First 
Second of 
Expiration(FEV1)  
Pre and post Absolute Liters (L) 
and percentage of 
predicted (%)  
Decreased in obstructive lung 
impairment <70-80% predicted  
FEV1/FVC Pre and post Direct ratio of 
patient’s values (%)  
1) < 70% characteristic of 
obstruction  
 2) > 70% characteristic of 
restriction  
    
Total Lung 
Capacity (TLC)  
N/A Absolute Liters (L) 
and percent of 
predicted (%)  
Restrictive lung impairment defined 
as TLC < 80% predicted  
    
Diffusion 
capacity/ Carbon 
Monoxide 
Diffusion 
N/A  Percent predicted 
(%)  
1) Decreased in obstruction with 
alveolar destruction 
2) Decreased in intrinsic restrictive 
lung impairment   
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3.8 General Analytic Strategy 
 Statistical analyses were performed using STATA® software (STATA11; 
STATAcorp, College Park, TX, USA).  Excel files were converted to STATA files using 
STAT/TRANSFER (Circle Systems; Seattle, WA, USA).  Standard data cleaning 
procedures were undertaken.   
To explore bivariate associations between continuous variables (i.e. cumulative 
asbestos exposure and FEV1) prior to multivariate regression analysis, the STATA 
command lowess was used to graphically assess the linearity of variables.  Lowess carries 
out a locally weighted regression, which draws a smooth (but not necessarily straight) 
line. The STATA command mkspline created variables containing a restricted cubic 
splines of any non-linear continuous variables with five knots. The use of restricted cubic 
splines provides a powerful and more biologically plausible method for identifying 
nonlinear relationships. 
Considering the primary purpose of this study was the prediction of pulmonary 
fibrosis, to eliminate predictor variables we used a P<0.20. R statistical program was 
used to create calibration plots to evaluate calibration of the prediction models.  	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3.9 Addressing Specific Study Questions  
 
Study Aim 1: What is the prevalence of pulmonary fibrosis in a well described asbestos-
exposed occupational cohort as determined by low-dose computed tomography?  
The number of cases of disease (pulmonary fibrosis) in the defined population 
during the given time will determine the prevalence.  
       
Study Aim 2: To assess multiple predictors of pulmonary fibrosis found by low-dose CT, 
specifically past asbestos exposure, pulmonary function indices (FVC, FEV1, FEV1/FVC, 
TLC, and DLCO), and smoking. 
 Logistic regression odds radios (ORs) and 95% confidence intervals were used to 
evaluate associations between predictors and the dichotomous outcome pulmonary 
fibrosis. Modeling was determined by a prior reasoning to determine which factors 
predicted CT-detected fibrosis.  Exposure to asbestos (age at first exposure, cumulative 
exposure), parameters of lung function (post FEV1, FVC, FEV1/FVC, TLC, DLCO), and 
smoking (ever versus never) will be predictor variables. All continuous variables (PFT 
variables) were kept in this format (not categorized). Only PFT’s that were performed 
prior to the CT-scan were used in the analysis.  To assess the contribution of predictors, 
especially pulmonary function test variables, to the model, the likelihood ratio statistic 
assessing the difference in likelihoods from the nested model was used.  
 The models ability to discriminate was assessed using the concordance or c-
statistic and/or its equivalent, the receiver operator characteristic area under the curve 
(ROC AUC). Model calibration (does the predicted probability match the observed 
probability) was assessed by evaluating how much the slope of the calibration line 
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(plotting the predicted probability versus the observed probability) deviated from the 
ideal of 1. The mean absolute error and 90th percentile absolute error in calibration were 
used to appraise calibration The Hosmer-Lemeshow goodness-of-fit test was also used to 
assess calibration of the model. To assess the fit of the model a significant Hosmer-
Lemeshow goodness-of-fit test indicates lack of fit.   
Logistic Post-Estimation Diagnostics   
 Overall model performance was evaluated with the R2 statistic.   
 
Study Aim 3: Is there an interaction between asbestos exposure and smoking that affects 
risk of pulmonary fibrosis?  
To assess the question of whether there is an interaction between asbestos exposure and 
smoking that affects pulmonary function in exposed workers, several steps were 
completed.  In order to test for interactions, new variables were created by multiplying 
variables of interest together to create interaction terms (Smoking Ever versus 
Never*Asbestos Exposure Duration Dichotomous). Asbestos exposure was dichotomized 
at greater than 29 years of exposure.  
Next, the term was entered in to the multivariable models along with the main 
effects terms used to create the new term to examine level of significant. The likelihood 
ratio test was examined to indicate a significant multiplicative interaction. 
Final Predictive Model 
After analyzing Aims 2 and 3, a final predictive model will be developed.  To 
determine which variables were retained in the final predictive model (and whether the 
smoking*asbestos interaction should be included), we kept all variables which had a p 
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value for the likelihood ratio test of <0.20. This was done to create a more clinically 
usable model.   
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CHAPTER IV- RESULTS 
 
4.1 Outline of Results 
 The results below will follow a specific sequence: 1) baseline characteristics, 2) 
lowess curves and restricted cubic splines for assessing non-linearity of predictor 
variables (mainly PFTS), 3) univariate models investigating splines, 4) full predictive 
model using logistic regression and all a priori explanatory variables, 5) model including 
an interaction term between smoking and asbestos exposure, which will be evaluated 
using the likelihood ratio test, and 6) the final model excluding all variables with a 
p>0.20. 
4.2 Study Population and Prevalence of Pulmonary Fibrosis (Aim 1) 
The following tables show the important baseline characteristics (Table 4). The 
mean age for the total population was 61.17 (SD=9.46) years of age.  Age was 
significantly different between those with and without fibrosis.  Participants with fibrosis 
were on average 65.14 (SD=8.99) years of age, while those without fibrosis had a mean 
age of 60.64 (SD=9.41) (p=0.0003). There was no significant difference in exposure to 
asbestos parameters between those with pulmonary fibrosis and those without. There was 
a higher frequency of current smokers in those with pulmonary fibrosis. Pack-years was 
not different between the two groups. The prevalence of pulmonary fibrosis was found to 
be 10.7% 95%CI (8.12—12.24).  
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Table 4: Baseline Characteristics of Asbestos Exposed Cohort Stratified by Presence/Absence of Low-Dose Computed 
Tomography Found Pulmonary Fibrosis (N = 613)  
 
 Total Population Pulmonary Fibrosis No Pulmonary Fibrosis p Value  
Mean age, years   61.12 65.14 60.64 <0.001 
Sex, (%)      
     Male 594 (97.38) 65 (100.00) 529 (97.06) 0.399 
     Female  16 (2.62) 0 (0.00) 16 (2.94)  
BMI, kg/m2  28.51 29.04 28.44 0.337 
Smoking (%)     
     Never 151 (24.59) 12 (18.46) 137 (25.14) 0.047 
     Former 116 (18.89) 7 (10.77) 108 (19.82)  
     Current  347 (56.51) 46 (70.77) 300 (55.05)  
Mean Pack-years smoking   17.70 20.21 17.40 0.283 
     
Asbestos Parameters     
     Mean age at first exposure, y 21.69 21.76 21.79 0.928 
     Mean duration of exposure, y  25.91 26.76 25.81 0.620 
     Time since first exposure, y 42.21 43.80 42.02 0.905 
     
COPD*† (%)  87 (14.26) 16 (24.62) 71 (13.03) 0.020 
Pleural Plaques† (%)  285 (46.72)  37 (56.92) 248 (45.50) 0.090 
     
Pulmonary fibrosis % N/A 65 
(10.66)95%CI(8.12-
12.24) 
545 (89.34) N/A 
     
Sarnia Cohort n= 320      
Post FVC  (mean % predicted)   103.49 97.82 104.35 0.024 
Post FEV1/FVC (mean) 74.35 75.66 74.16 0.353 
TLC  (mean)  99.66 93.69 100.50 0.009 
DLCO (mean) 89.61 84.70 90.32 0.110 
DLCO/ VA (mean)  100.34 97.67 100.73 0.414 
     
*COPD= chronic obstructive pulmonary disorder 
†Low-dose computed tomography found (LDCT) pulmonary fibrosis, pleural disease and COPD at baseline 
‡P-values were computed for age, body mass index, pack-years, asbestos latency, FEV1(L), FVC(L), TLC(L), DLCO, and DLCO/VA using the 
t test; for dichotomous variables; male, female, LDCT found pulmonary fibrosis, COPD, pleural plaques the Fisher exact test was used  
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4.3 Assessing Linearity of Continuous Variables using Lowess  
The lowess technique draws a smooth line representing the average value of the 
variable on the y-axis as a function of the variable on the x-axis. In the case of binary 
outcome (presence/absence of LDCT found pulmonary fibrosis), these average the 
outcome proportions over groups whose size was specified by the bandwidth of the 
selected smoothing method.   Lowess curves were generated for all predictor continuous 
variables (i.e., age, height, FEV1, FVC, FEV1/FVC, DLCO, and TLC etc.). See 
Appendix D for all lowess curve. Below are the lowess curves for FVC and FEV1 both 
showing a non-linear relationship with probability of LDCT found pulmonary fibrosis. 
Restricted cubic splines with five knots were created for all variables which were visibly 
non-linear when examining the lowess curves.  These variables were: FVC, FEV1, 
FEV1/FVC, TLC, and DLCO. All variables were percent predicted and post-
bronchodilator due to higher accuracy, since pre-bronchodilator lowess curves appeared 
visually similar and when put into a preliminary model, no absolute measure significantly 
predicted pulmonary fibrosis. The lowess curve for post-FVC (Figure 8) shows a 
downward relationship with fibrosis to approximately 110% and then an upward 
relationship to 160%.   The lowess curve for post-FEV1 (Figure 9) is flat, then goes 
downward to approximately 110% and then upward to 150%.  
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Figure 8: Lowess Curve for FVC and Probability of LDCT Found Pulmonary Fibrosis. 
X-axis is the Post-Bronchodilator Forced Vital Capacity (FVC). Y-axis is the Probability 
of Fibrosis. 
 
 
Figure 9: Lowess Curve for FEV1 and Probability of LDCT Found Pulmonary Fibrosis.  
X-axis is the Post-Bronchodilator Forced Expiratory Volume (FEV1). Y-axis is the 
Probability of Fibrosis. 
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4.4 Predictive Models for Pulmonary Fibrosis (Aim 2) 
Presented in Table 5 are the univariate models investigating splines of pre- and 
post-bronchodilator PFT variables including FVC, FEV1, FEV1/FVC, TLC and DLCO.  
Both pre- and post-bronchodilator FVC and FEV1 reached statistical significance based 
on p-values and 95%CI (the post FEV1 had a trend towards significance). The proper 
evaluation of splines should be as a group using the likelihood ratio test.  
4.4.1 Full Predictive Model for Pulmonary Fibrosis  
The full predictive model using logistic regression including all a priori variables 
based on well-established predictors from the literature is shown in Table 6. Table 6 also 
contains the likelihood ratio tests for each variable listed, assessing the variables 
contribution to the model. Age contributed to the model with a LRT of 0.1218. Both the 
post-FVC and post-FEV1 splines were included in the predictive model with LRT’s of 
0.0012 and 0.0240. Dichotomous (ever versus never) smoker variable had an effect 
estimate of 2.62 and contributed to the model with a LRT of 0.0538. Though age at first 
asbestos exposure, dyspnea and pleural plaques did not reach a p value of < 0.20 they 
were retained in the model due to a priori reasoning based on past literature and expert 
opinion.  The ROC AUC, which indicates an overall measure of classification accuracy, 
of the predictive model was 0.7493.  The goodness of fit test yielded a value of 0.2461, 
indicating a fit for the model. Calibration and the calibration plot was accomplished using 
200 repetition bootstrapping.  The slope of the apparent calibration line deviates from 1 
by 0.3319.  
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Additional analyses that included the main clinical and radiologic variables 
described in Table 4 (e.g., BMI, radiologic evidence of COPD or plaques) found that 
none of these contributed to the predictive model (LRT p>0.20 for each variable).  
The predictive model was stratified by smoking status (Appendix F). Due to small 
numbers of smokers (n=65), confidence intervals were extremely wide and not included 
in the body of the results. 
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Table 5: Univariate Models of Pulmonary Function Test Splines- Pre and Post 
Bronchodilator Predicting LDCT-Found Pulmonary Fibrosis.   
 
Restricted Cubic Splines OR (95%CI) p-value 
Pre-FVC%1 0.94 (0.90-0.99) 0.03 
Pre-FVC%2 1.05 (0.88-1.25) 0.55 
Pre-FVC%3 0.98 (0.48-1.96) 0.96 
   
Post-FVC%1 0.94 (0.89-0.99) 0.03 
Post-FVC%2 1.07 (0.90-1.28) 0.43 
Post-FVC%3 0.89 (0.41-1.94) 0.77 
   
Pre-FEV1%1 0.95 (0.92-0.99) 0.03 
Pre-FEV1%2 1.05 (0.95-1.17) 0.28 
Pre-FEV1%3 0.84 (0.46-1.57) 0.60 
   
Post-FEV1%1 0.96 (0.92-1.00) 0.09 
Post-FEV1%2 1.03 (0.92-1.15) 0.59 
Post-FEV1%3 0.99 (0.52-1.91) 0.99 
   
Pre-FEV1_FVC1 0.94 (0.89-1.00) 0.07 
Pre-FEV1_FVC2 1.12 (0.98-1.29) 0.09 
Pre-FEV1_FVC3 0.43 (0.12-1.57) 0.20 
   
Post-FEV1_FVC1 0.97 (0.91-1.03) 0.32 
Post-FEV1_FVC2 1.05 (0.91-1.21) 0.53 
Post-FEV1_FVC3 1.16 (0.31-4.32) 0.83 
   
TLC1 0.96 (0.91-1.02) 0.25 
TLC2 1.02 (0.86-1.19) 0.83 
TLC3 0.95 (0.36-2.47) 0.91 
   
DLCO1 0.97 (0.93-1.02) 0.25 
DLCO2 1.03 (0.86-1.22) 0.74 
DLCO3  0.95 (0.47-1.88) 0.88 
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Table 6: Full Logistic Regression Model Predicting LDCT Found Pulmonary Fibrosis in 
a Cohort of Asbestos Workers (n=320)  
 
 Odds Ratio (95%CI) P Value Likelihood Ratio 
Test 
P Value  
VARIABLES     
Age (per 10 years)  1.03 (0.99-1.07) 0.124 0.122 
Age at first asbestos 
exposure (years) 
0.98 (0.93-1.03) 0.382 0.369 
Dyspnea  1.59 (0.74-3.36) 0.214 0.218 
Smoking (Ever vs. Never)  2.62 (0.91-7-54)  0.074 0.054  
Post FVC Splines (%) 0.93 (0.86-0.99) 0.049 0.001 
 1.25 (0.75-2.08) 0.396  
 0.09 (0.00-2.11) 0.136  
 132 (0.93-1887) 0.053  
Post FEV1 Splines (%)  1.01 (0.94-1.07) 0.839 0.024 
 0.92 (0.69-1.24) 0.604  
 8.49 (0.62-115) 0.109  
 0.01 (0.00-0.87) 0.044  
Pleural Plaques  1.58 (0.74-3.36) 0.324 0.225 
MODEL 
PERFORMANCE  
   
R-square Stata  0.133   
Hosmer Lemeshow 
goodness-of –fit 
p=0.246   
C-statistic  0.749   
    
Calibration    
  Calibration slope 0.668   
  Mean absolute error 0.022   
  90thpercentile absolute 
error 
0.046    
*Variables were included into the predictive logistic model by a priori reasoning based on literature review 
and expert opinion (pulmonologist) 
† Dichotomized smoking variable as Ever versus Never smoker  
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Figure 10: Calibration Plot of Actual Versus Predicted Pulmonary Fibrosis in Full 
Predictive Model. Calibration Used 200 Boot-Strap Repetitions on 329 Participants to 
Generate Curves. The Mean Absolute Error was 0.022.  
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4.4.2 Predictive Model Including Smoking*Asbestos Interaction (Aim 3)  
 Table 7 presents the predictive model including the main effect terms of smoking 
dichotomized (ever versus never), asbestos exposure duration dichotomized and the 
interaction term between these two variables.  The likelihood ratio test shows that the 
interaction does not independently predict pulmonary fibrosis with a value of 0.225. 
Though the C-statistic does increase to 0.760 when comparing the models with and 
without the interaction term using roccomp, there is not a significant different (p=0.212). 
Roccomp is a test of equality for ROC areas.  
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Table 7: Logistic Regression Model Predicting LDCT Found Pulmonary Fibrosis in a 
Cohort of Asbestos Workers (n=329) - Investigating Smoke-Asbestos Interaction   
 
 Odds Ratio (95%CI) P Value Likelihood Ratio 
Test 
P Value  
VARIABLES     
Age (per 10 years)  1.03 (0.99-1.08) 0.111  
Age at first asbestos 
exposure (years) 
0.97 (0.92-1.03) 0.340  
Dyspnea  1.60 (0.77-3.31) 0.210  
Post FVC Splines (%) 0.92 (0.85-0.99) 0.044  
 1.25 (0.74-2.10) 0.402  
 0.09 (0.00-2.30) 0.149  
 116.14 (0.78-
17360.45) 
0.063  
Post FEV1 Splines (%)  1.01 (0.95-1.07) 0.838  
 0.93 (0.69-1.25) 0.629  
 7.78 (0.57-106.44) 0.124  
 0.00 (0.00-1.06) 0.053  
Pleural Plaques  1.67 (0.77-3.58) 0.189  
Smoke Dichotomous 6.43 (0.79-52.51) 0.083  
Asbestos Duration 
Dichotomous 
2.82 (0.28-28.80) 0.381  
Smoke*Asbestos 
Interaction 
0.25 (0.02-2.80) 0.260 0.225 
MODEL 
PERFORMANCE  
   
R-square Stata  0.140   
Hosmer Lemeshow 
goodness-of –fit 
p=0.142   
C-statistic  0.760   
    
*Variables were included into the predictive logistic model by a prior reasoning based on literature review 
and expert opinion (pulmonologist) with backward selection 
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Figure 11: Comparison of ROC curves for LDCT Found Pulmonary Fibrosis- Full 
Predictive Model with Smoke_Asbestos Interaction versus Without Interaction.  
(p=0.212) 
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4.4.3 Development of a Final Predictive Model: Comparing Predictive Models With 
and Without Variables with P>0.20 
 Table 8 presents our predictive model excluding variables with a p-value of >0.20 
including age at first asbestos exposure, dyspnea and pleural plaques.  Without these 
variables the R-square decreases from 0.133 to 0.118, the C-statistic decreases from 
0.749 to 0.738 (Figure 12) and the measures of calibration, including mean absolute error 
(0.022 to 0.023) and 90th percentile absolute error (0.046 to 0.054) become less 
significant shown in Figure 13.  However, the fit of the model increases from 0.246 to 
0.428 when excluding these variables.  
Table 8: Logistic Regression Model Predicting LDCT Found Pulmonary Fibrosis in a 
Cohort of Asbestos Workers Excluding Variables with P>0.20 (n=320)  
 
 Odds Ratio (95%CI) P Value  
VARIABLES   
Age (per 10 years) 1.03 (0.99-1.07) 0.111 
Smoking Dichotomized 2.91 (1.02-8.24) 0.045 
Post FVC Splines (%)  0.92 (0.86-1.00) 0.054 
 1.25 (0.75-2.08) 0.389 
 0.09 (0.00-2.03) 0.131 
 133.64 (0.98-18209) 0.051 
Post FEV1 Splines (%)  1.01 (0.95-1.07) 0.693 
 0.91 (0.68-1.21) 0.502 
 9.54 (0.72-127) 0.088 
 0.01 (0.00-0.72) 0.037 
MODEL PERFORMANCE    
R-square Stata  0.118  
Hosmer Lemeshow 
goodness-of-fit 
p=0.428  
C-statistic  0.738  
Roccomp test   p=0.430  
Calibration   
  Calibration slope 0.692  
  Mean absolute error 0.023  
  90th percentile absolute 
error 
0.054   
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Figure 12: Comparison of ROC curves for LDCT Found Pulmonary Fibrosis- Full 
Predictive Model versus Model Excluding with Variables p> 0.2 (p=0.430)   
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Figure 13:  Calibration Plot of Actual Versus Predicted Pulmonary Fibrosis in Model 
Excluding Variables with p>0.20. Calibration Used 200 Boot-Strap Repetitions on 338 
participants to Generate Curves. The Mean Absolute Error was 0.023.  
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CHAPTER V- DISCUSSION & CONCLUSIONS 
5.1 Key Findings  
Our study found the prevalence of pulmonary fibrosis in this asbestos exposed 
cohort to be 10.7% (Aim 1).  Previous studies investigating the association between 
exposure to asbestos, smoking, abnormal lung function and pulmonary fibrosis have 
focused on predicting pulmonary function, or having pulmonary function indices as the 
dependent outcome variable (Alfonso et al., 2004; Begin et al., 1983; Kilburn & 
Warshaw, 1994; Ohar et al., 2004; Wang et al., 2006). However, it has been reported that 
pulmonary dysfunction precedes chest x-ray and CT findings of pneumoconiosis, 
suggesting the importance of pulmonary function tests in screening for early disease and 
prediction of subsequent disease, such as pulmonary fibrosis, in those exposed to asbestos 
(Tonori et al., 2005).  To our knowledge the current study is the second (Paris et al., 
2008) to predict pulmonary fibrosis in those exposed to asbestos and the first to 
investigate other predictive variables beyond simply asbestos exposure.  Our final 
predictive model for prediction of LDCT-found pulmonary fibrosis, included the 
following predictive variables: age, smoking dichotomized, post FVC(%) splines, and 
post FEV1(%) splines. This model had an ROC-AUC of 0.738 and a calibration slope 
0.692. These measures of predictive performance suggest moderately good predictive 
ability (Aim 2). Our study did not find a significant interaction between smoking, 
asbestos exposure and pulmonary fibrosis (Aim 3).  
The following discussion will first review the main predictors in our final model 
(A), including current results compared to past literature, starting with a discussion of 
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asbestos exposure. This will be followed by a discussion of strengths and limitations of 
the study design and analysis (B). Finally, there will be a discussion of the clinical utility 
and future directions of this research (C). 
 
5A. PREDICTORS OF FINAL MODEL 
5.1.1 Asbestos Exposure 
All subjects underwent a face-to-face interview in order to obtain occupational 
histories. Therefore our measure of asbestos exposure was self-report. Several parameters 
were calculated including time since first exposure, duration and age at first exposure to 
asbestos. All asbestos exposure indices were not different when comparing those with 
and without pulmonary fibrosis diagnosed by LDCT (Table 4) and none significantly 
predicted pulmonary fibrosis in our model as tested by the likelihood ratio test (Table 6). 
There are three major considerations for asbestos exposure assessment: 1. exposure 
intensity (concentration of asbestos fibers), 2. latency period (time since first exposure), 
and 3. duration of exposure. A recent study by Paris et al. (2008) found that time since 
first exposure and exposure intensity were predictive of asbestosis and pleural plaques, 
but not duration of exposure. The authors suggested these two parameters; time since first 
exposure and dose, must be included in the definition of high risk populations suitable for 
screening of these diseases (pleural plaques and asbestosis). In our predictive model only 
age at first exposure to asbestos was included as a predictor of LDCT-found pulmonary 
fibrosis (OR=0.98, 95%CI: 0.93-1.03) (Table 6). The discrepancy between the current 
study and Paris et al. may be due to different analytic techniques or error in the 
measurement of asbestos exposure.  The current study ascertained asbestos exposure 
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through a self-reported face-to-face questionnaire, which was not previously validated 
and administered by a research coordinator. Also, our assessment of asbestos exposure 
lacked systematic measurements of dust or fiber concentrations. We used exposure 
duration, latency and age since first exposure as surrogates of personal exposure, which 
might have led to exposure misclassification.  Also, since all participants were found to 
have some exposure, differences or dose-responses were difficult to investigate. In the 
study by Paris et al. more precise assessments of asbestos exposure were obtained by 
occupational hygiene measurements and a job-exposure matrix. A quantitative 
assessment of occupational exposure was obtained using a specific job-exposure matrix 
elaborated from actual airborne measurements collected in the plant. However, a study by 
Wang et al. (2006) used a more crude estimate of asbestos exposure obtained from a face-
to-face interview and still found that exposure to asbestos (yes versus no) and cumulative 
exposure years, without any measurement of fiber concentrations, was associated with 
reduced FVC, FEV1 and DLCO in cross-sectional study of factory workers. However, 
we did not evaluate PFT variables as an outcome. Similar results were found from a 
cohort study conducted in Western Australia with regard to the relationship among 
asbestos exposure and changes in lung function in which asbestos fiber concentration was 
estimated from the results of a survey carried out at worksites in 1966 where particle 
counts were performed (Alfonso et al., 2004).  
 
5.1.2 Pulmonary Function 
Currently, PFTs are a widely accepted tool in the medical surveillance of those 
exposed to asbestos, both for worker’s compensation and monitoring of disease 
	  
	  
75	  
	  
progression.  Moreover, PFT’s can play a role in early detection, diagnosis and 
prevention of disease (Wang et al., 2006).  Our study found that FEV1 and FVC 
restricted cubic splines significantly predicted LDCT found pulmonary fibrosis. Our 
findings were similar to Wang et al. 2006, in which workers with asbestosis had the 
lowest FVC followed by asbestos workers without asbestosis.  Decreased FVC would be 
the optimal index to reflect the severity of parenchymal abnormalities. DLCO was 
simultaneously lower in asbestos workers, regardless of chest x-ray found asbestosis 
(Wang et al., 2006). The authors suggest this indicates that reduced diffusing capacity 
may be a sensitive index to reflect the earliest physiological changes due to asbestos 
exposure. Diffusing capacity is a measure of the ability of the lung to transfer gas. 
Diffusion of the lungs is most efficient when the surface area for gas exchange is high 
and the blood is readily able to accept the gas being exchanged. DLCO is decreased 
when: 1) conditions that minimize the ability of blood to accept and bind to the gas that is 
diffusing (anemia), 2) conditions that decrease the surface area of the alveolar-capillary 
membrane (emphysema, pulmonary embolism), and 3) conditions that alter the 
membrane or increase its thickness (pulmonary fibrosis). Wang et al., 2006 hypothesized 
that it was likely that DLCO changes would correlate well with high resolution CT 
scanning changes and pathologic findings at early stages.  Our study is the first to 
correlate LDCT with PFT measures and did not find that reduced diffusing capacity 
predicted LDCT pulmonary fibrosis (Table 6).    
5.1.3 Smoking-Asbestos Interaction 
Previous studies generally agree that asbestos exposure is associated with 
restrictive lung impairment along with reduced diffusing capacity.  It is well established 
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that obstructive lung impairment is also associated with asbestos exposure, cigarette 
smoke, or if there is an interaction between asbestos and smoking.  Some of the 
controversy may be due to variations of occupational conditions, type of asbestos 
exposure, differing analytic strategies, difference in intensity of exposure, severity of 
pathological changes, and age.   Previous reports have suggested that cigarette smoking 
enhances the development of interstitial fibrosis in workers exposed to asbestos. No 
interaction or joint effects were observed between asbestos exposure and smoking in our 
study.  Results from a previous studies suggests that smoking and asbestos exposure act 
independently (additively) rather than synergistically (multiplicative) on the level and 
rate of decline in lung function in the cohort (Alfonso et al., 2004; Wang et al., 2006). 
 
5B. STRENGTHS AND LIMITATIONS 
5.2 Strengths  
 
5.2.1 Study Design 
This study has several strengths. The current study yielded similar results to those of 
Alfonso et al., 2004, a cohort conducted in Western Australia with subjects solely 
exposed to crocidolite asbestos, with regard to the relationships among asbestos 
exposure, smoking and the changes in lung function. It is interesting to note that although 
subjects were sampled based on exposure (not outcome status) this study is technically a 
cohort. However, no new cases of pulmonary fibrosis were found beyond the initial 
LDCT scan after four years of follow-up, therefore the study is cross-sectional in nature 
and thus does not allow us to determine a clear exposure-response relationship. This also 
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means there is no true ‘time-to-event’. A longer follow-up period, such as ten years, may 
yield new cases of pulmonary fibrosis. The study by Wang et al., 2006, was a cross-
sectional design and they acknowledged that they were inherently limited to determining 
clear causal effects of exposure to asbestos and smoking. Yet, similar results such as 
those from the Western Australian cohort and the present cohort were also found.  
5.2.2 Variables 
 This study made the best use of the continuous predictor PFT variables, by 
keeping them continuous and not categorizing them.  Categorizing would have led to 
serious statistical inference problems including bias, and loss of power. Merely excluding 
subjects with incomplete data from analysis is a mistake.  The amount of missing data at 
baseline should be carefully documented, including the proportion of missing values for 
each variable being analyzed and a description of the types of subjects which have 
missing variables. In the current study, 41.4 % of subjects were missing a pulmonary 
function test.  This was dealt with by only including those from the Sarnia cohort, which 
had complete pulmonary function test information. There was no missing data for the 
main outcome variable of LDCT-pulmonary fibrosis because every subject had at least 
the baseline scan where they were categorized as 1= pulmonary fibrosis, 0=no pulmonary 
fibrosis or 8=bilateral apical fibrosis. Category 8 was not included as a case of pulmonary 
fibrosis. Isolated bilateral fibrosis is not typically associated with asbestosis. Apical 
fibrosis would only be seen in asbestosis if there was extensive fibrotic disease 
throughout the lung.  
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5.2.3 Low-Dose Computed Tomography 
 Another major strength of this study was how the outcome was ascertained by 
LDCT. There have been many previous radiological-functional correlation studies in 
asbestos exposed populations either with chest x-ray (Alfonso et al., 2004; Ohar et al., 
2004; Wang et al., 2006 ) or computed tomography (Aberle, Gamsu, & Ray, 1988; 
Staples, Gamsu, & Ray, 1988; Neri et al., 1996; Sette et al., 2004). However, this is the 
first study correlating pulmonary function indices with LDCT found pulmonary fibrosis. 
Though high resolution computed tomography does have increased sensitivity and 
specificity in comparison to chest x-ray, its use for screening and diagnosis is 
questionable owing to the increased radiation burden and high economic cost (Xaubet et 
al., 1998). Therefore using LDCT is attractive due to the reduced radiation burden in 
those already at high risk for many conditions.  
5.3 Limitations   
 
5.3.1 Asbestos Measurement 
This study is also vulnerable to non-differential misclassification bias (biasing the 
risk estimates toward the null).  Non-differential misclassification bias occurs when the 
degree of misclassification of exposure is independent of case-control status (fibrosis vs. 
no fibrosis), or vice-versa (Szklo & Nieto, 2006).  
The manner in which asbestos exposure was measured, by self-report is a 
limitation.  The superior method of asbestos exposure ascertainment would be the use of 
systematic measurements of dust or fiber concentrations along with the aid of an 
industrial hygienist (Teschke et al., 2002). Wang et al., 2006 used exposure duration as a 
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surrogate of personal exposure, which also may have lead to exposure misclassification.  
In a study of former crocidolite workers in Western Australia, job histories were obtained 
from employment records. Fiber concentration for all job categories was estimated from 
results of a survey of airborne respiratory fibers crocidolite in 1966.  Each subject’s 
cumulative exposure was calculated by adding over all their different jobs the product of 
estimated or measured fiber concentration and the length of time in that job (Alfonso et 
al., 2004). 	  
In our study questionnaires were used to ask about subject’s occupational history, 
use of specific agents, trade name products or specific type of asbestos in a face-to-face 
interview. Though studies that assess exposure with direct questions to participants, such 
as “Were you ever exposed to asbestos?”, are prone to incorrect measurement and may be 
vulnerable to widely varied interpretations among participants of what constitutes 
exposure, but data derived in this crude fashion can still yield useful information.  A 
study comparing next-of-kin assessment, expert assessment and the use of a job exposure 
matrix found that disease-exposure odds ratios based on next-kin respondents are inflated 
by recall-bias, whereas those from the job exposure matrix are attenuated.  Also job 
exposure matrix exposure categorization based on next-of-kin data predicted asbestos 
levels that matched expert assessment better than only the JEM (Nam, 2005). Therefore 
among the asbestos exposure assessment methods in use today, expert assessment is the 
best approach, however it can also have low validity and reliability if there is not proper 
training of the expert, and if not enough information is provided in the detailed 
occupational history of subjects.  All exposure assessment methods, whether by experts 
or self-report have limitations and can have low validity and reliability. 
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5.3.2 Classification of Pulmonary Fibrosis    
Classification of pulmonary fibrosis (dichotomous present/not present) may be 
inappropriate. Despite an absence of an internationally accepted classification tool for 
pulmonary fibrosis  as determined by CT, Huuskonen et al. recorded several specific HR-
CT parenchymal abnormalities and found good inter- and intraobserver agreement.  The 
parenchymal abnormalities were: (i) subpleural dependent opacity, (ii) subpleural 
curvilinear opacities, (iii) subpleural perpendicular lines (septal lines), (iv) parenchymal 
bands, (v) small irregular parenchymal opacities, and (vi) honeycombing.  The severity of 
each abnormality was recorded from mild to profuse. Receiver-operating characteristic 
(ROC) curve area under the curve was significantly greater for HR-CT fibrosis score 
(0.89) than for the ILO radiographic classification (0.76) (P<0.0001) (Huuskonen et al., 
2005). It has been suggested that this type of semi-quantitative HRCT scoring system 
could be of use when an international HR-CT classification is designed for occupational 
lung disease (American Thoracic Society, 2004).   It would be interesting to apply the 
criteria of Huuskonen to our dataset in the future however the crude dichotomous 
classification was sufficient for the purpose of this study.  Note that screening for 
mesothelioma was the primary aim of this cohort; therefore detailed fibrosis data was 
simply not available.  
5.4 Unanswered questions 
 
5.4.1 Descriptive Statistics of Asbestos-Related Diseases   
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There is a clear lack of descriptive statistics regarding asbestos related disease in 
Ontario, including mesothelioma and asbestosis.  This study describes the prevalence of 
pulmonary fibrosis in a well described asbestos-exposed cohort of workers in Ontario as 
determined by LDCT, to be 10.7%.   
 
5.4.2 Classification of Pulmonary Fibrosis by CT 
As previously noted, there have been attempts to describe several specific CT 
parenchymal abnormalities of asbestosis including: (i) subpleural dependent opacity, (ii) 
subpleural curvilinear opacities, (iii) subpleural perpendicular lines (septal lines), (iv) 
parenchymal bands, (v) small irregular parenchymal opacities, and (vi) honeycombing 
(45). Proper quantification of pulmonary fibrosis (not a simple present/absent) based on 
Huuskonen et al. is necessary.  Copley et al. used multivariate regression and found a 
combination of CT features most closely linked to individual pulmonary function indices 
has been identified and tested in separate groups. Thus, for a given reduction in TLC or 
DLCO, the proportion of the deficit ascribable to fibrosis, diffuse pleural thickening and 
emphysema can be preliminarily quantified (Copley et al., 2001).  Validating this 
approach to CT-found pulmonary fibrosis quantification could be accomplished using the 
current dataset.    
 
5.4.3 Investigating Age, Birth and Cohort Effects 
 Age is a strong risk factor for many health outcomes and frequently associated 
with various risk factors.  Therefore even if investigating the effect of age on an outcome 
is not the primary study aim, it is important to assess its relationship with outcomes and 
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exposures (given the potential confounding effect) (Szklo & Nieto, 2006).  Age effect 
occurs when there is a change in the rate of a condition according to age, irrespective of 
birth cohort and calendar time. For many diseases, exposures have a cumulative effect 
that is expressed over long periods of time. Long latency periods and cumulative effects 
characterize, for example, numerous exposure/disease associations, such as smoking/lung 
cancer, radiation/thyroid cancer, and in our case asbestosis or mesothelioma/asbestos 
(Szklo & Nieto, 2006). Cohort effect is a change in the rate of a condition according to 
the year of birth. In addition to age and cohort effects, period effect occurs when there is 
a change in the rate of a condition affecting an entire population at some point in time 
(e.g. date of asbestos ban in Canada, Hiroshima, war, new treatment etc.). The term 
“period effect” is frequently used to describe a global shift or change in trend that affects 
the rates across birth cohort and age groups (Szklo & Nieto, 2006).  With true 
longitudinal follow-up, it would be interesting to use our data to estimate the parameters 
of a birth-cohort and age effect to determine patterns of mesothelioma and asbestosis in 
the Sarnia-Lambton, Ontario population. Unfortunately we do not have the data to do 
this.   
 
5C. CLINICAL UTILITY AND FUTURE DIRECTIONS 
5.5 Association versus Prediction Studies 
 Most previous studies have focused on associations between various clinical and 
radiological parameters and pulmonary fibrosis. One exception to this is a study by Paris 
et al., 2008, however this study only examined various parameters of asbestos exposure, 
and ignored other key clinical variable. No one has previously looked at PFTs in a 
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predictive model. Therefore, the current analysis is unique because it is a predictive 
model of pulmonary fibrosis which looks at PFT variable and multiple other clinical 
variables. It should also be made clear that variables which are associated may not be 
useful as a predictor. One clear example in the current study is of chronic obstructive 
pulmonary disease. Although COPD is univariately significantly associated with 
pulmonary fibrosis (Table 4), COPD did not contribute in the predictive model.  
5.6 Clinical Utility of the Final Predictive Model  
 There are several potential uses of this predictive model. First this model could be 
used for risk stratification to determine which asbestos exposed individuals should 
undergo CT screening for pulmonary fibrosis. Currently there are no guidelines as to who 
should actually go for CT screening. If all asbestos exposed individuals were to have CT 
scans it would be expensive and people might be receiving radiation which is not 
necessary. Further, the original Princess Margaret Hospital screening program has not 
provided much evidence to support screening of everyone with asbestos exposure (i.e., 
though a number of cases 
 of lung cancer and mesothelioma were diagnosed during the course of screening, the 
majority of cases were identified in between screening scans).  Therefore, it is unlikely 
we would ever utilize CT screening for everyone so if we want to identify fibrosis we 
could use this prediction model to identify who are the highest risk individuals. In these 
people CT screening may be feasible. Currently, most research has been focused on using 
biomarkers to identify individuals with mesothelioma (e.g. soluble mesothelin related 
peptide) (Pass et al., 2008).  In the future there may be potential biomarkers for 
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pulmonary fibrosis (particularly biomarkers within the inflammatory pathway). 
Developing a baseline predictive model would be highly useful when determining 
whether the addition of a biomarker would improve the model (e.g. tested by the 
likelihood ratio test). There are also several ways in which clinical implementation could 
happen with a predictive model. One is plugging values into software of the model or to 
develop a visual nomogram which then deliver the risk of having pulmonary fibrosis by a 
specific individual. The level of risk would help guide clinicians to proceed with 
additional testing (or not). Having identified the prevalence in this study this can be used 
as a baseline value to input into the nomogram. A second method would be to develop an 
actual scoring system based on the predictive model which is simplified for clinicians to 
use, however this may prove difficult with the inclusion of restricted cubic spline for 
pulmonary function test variables. However, it is important to note that though the 
present model did have moderately good predictive ability, it is not ready for clinic al 
implementation.  
5.7 Future Directions 
 There are several things that should be done before this predictive model could be 
ready for clinical implementation. First the model should be validated in a larger and 
independent set of participants.  As stated before, it would be interesting to use this 
model as a baseline to test the benefit of various potential biomarkers. And lastly it would 
be useful to get a better definition of pulmonary fibrosis (possibly multiple levels of 
severity) for a better predictive model.  
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5.8 Conclusion 
This study has several important contributions.  The description of the prevalence 
of pulmonary fibrosis in this cohort in Ontario is new data. The need for descriptive 
statistics for asbestos-exposed workers in Ontario is very important. Also this is only the 
second study to create a predictive model for pulmonary fibrosis in asbestos-exposed 
individuals beyond simply asbestos exposure.  
 This study describes the prevalence of pulmonary fibrosis in a well described 
asbestos-exposed cohort of workers in Ontario at 10.7%. Because of the clear lack of 
descriptive statistics regarding asbestos related disease in Ontario, including 
mesothelioma and asbestosis, this finding is important. Our final predictive model for 
prediction of LDCT-found pulmonary fibrosis, included the following predictive 
variables: age, smoking dichotomized, post FVC(%) splines, and post FEV1(%) splines. 
This model had an ROC-AUC of 0.738 and a calibration slope 0.692. These measures of 
predictive performance suggest moderately good predictive ability. Our study did not find 
a significant interaction between smoking, asbestos exposure and pulmonary fibrosis. 
Though chest radiography has its advantages (cost and availability), CT is 
increasingly useful in the context of investigation of asbestos-exposed individuals.  The 
limitations of chest radiography, and its inferiority compared to CT is becoming accepted 
worldwide.  CT plays an important and central role in the clinical and medico-legal 
assessment of individuals with suspected asbestos-induced parenchymal lung disease. 
Though radiological evaluations of asbestos-exposed individuals are relatively sensitive 
and reproducible for these purposes, their frequent use is questionable owing to the 
radiation burden and their high economic cost.  The current study provides the first much 
needed evaluation of the prediction of low dose computed tomography found pulmonary 
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fibrosis. The current prediction model could be developed further to improve the 
predictive ability (through larger, better annotated samples or through the addition of 
biomarkers) to decipher who is at highest risk for pulmonary fibrosis.  These variables 
can also be used to stratify high-risk populations suitable for screening of pulmonary 
fibrosis.   
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APPENDIX A- Sample Consent Form for Subjects Involved in the Early 
Diagnosis of Mesothelioma and Lung Cancer in Prior Asbestos Workers Study  
	  
 
 
CONSENT	  FORM	  
	  
TITLE	  :	   Low-dose Computed Tomography for the Early  
Diagnosis of Mesothelioma and Lung Cancer in 
Prior Asbestos Workers 
	  
	  
INVESTIGATOR:	  	   Dr. Demetris Patsios MD, Telephone Number 416- 586-4200 
extension 5598	  
	  
	  
You	  have	  been	  asked	  to	  take	  part	  in	  a	  research	  study.	  This	  study	  is	  designed	  to	  detect	  
mesothelioma	  and	  lung	  cancer	  in	  an	  early	  stage.	  Before	  agreeing	  to	  participate	  in	  this	  
study,	  it	  is	  important	  that	  you	  read	  and	  understand	  the	  following	  explanation	  of	  the	  
proposed	  study	  procedures.	  The	  following	  information	  describes	  the	  purpose,	  procedures,	  
benefits,	  discomforts,	  risks	  and	  precautions	  associated	  with	  this	  study.	  It	  also	  describes	  
your	  right	  to	  refuse	  to	  participate	  or	  withdraw	  from	  the	  study	  at	  any	  time.	  In	  order	  to	  
decide	  whether	  you	  wish	  to	  participate	  in	  this	  research	  study,	  you	  should	  understand	  
enough	  about	  its	  risks	  and	  benefits	  to	  be	  able	  to	  make	  an	  informed	  decision.	  This	  is	  
known	  as	  the	  informed	  consent	  process.	  Please	  ask	  the	  study	  doctor	  or	  study	  staff	  to	  
explain	  any	  words	  you	  don’t	  understand	  before	  signing	  this	  consent	  form.	  Make	  sure	  that	  
all	  your	  questions	  have	  been	  answered	  to	  your	  satisfaction	  before	  signing	  this	  document.	  
	  
Background	  and	  Purpose	  
Asbestos	  exposure	  may	  result	  in	  several	  different	  diseases	  to	  the	  lung	  and	  to	  the	  lining	  of	  
the	  lung,	  the	  so-­‐called	  pleura.	  Mostly	  they	  are	  benign,	  but	  there	  are	  two	  common	  
malignant	  diseases	  in	  people	  with	  prior	  asbestos	  exposure,	  the	  so-­‐called	  mesothelioma	  –	  
which	  originates	  from	  the	  pleura	  -­‐	  and	  cancer	  of	  the	  lung.	  Symptoms	  of	  any	  of	  these	  
malignant	  diseases	  generally	  do	  not	  appear	  for	  10-­‐35	  years	  after	  the	  first	  asbestos	  
exposure,	  and	  include	  shortness	  of	  breath,	  chronic	  or	  new	  cough,	  coughing	  of	  blood,	  
chest	  pain	  or	  weight	  loss.	  Unfortunately,	  these	  symptoms	  are	  most	  often	  causes	  by	  very	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advanced	  diseases,	  when	  patients	  can	  no	  longer	  be	  cured.	  Currently	  there	  is	  no	  accepted	  
tool	  for	  the	  early	  diagnosis	  of	  mesothelioma	  or	  lung	  cancer	  in	  asbestos-­‐exposed	  subjects	  
available.	  Standard	  of	  care	  includes	  regular	  chest	  radiographs,	  which	  are	  not	  sufficient	  to	  
show	  mesothelioma	  or	  lung	  cancer	  in	  an	  early	  stage.	  
In	  the	  last	  decade,	  computed	  tomography	  (CAT-­‐scan,	  CT)	  has	  been	  successfully	  
developed	  for	  the	  early	  detection	  of	  lung	  cancer	  in	  smokers,	  both	  worldwide	  and	  in	  
Toronto,	  under	  the	  leadership	  of	  Dr.	  Roberts.	  Physicians	  of	  the	  University	  Health	  Network	  
hope	  to	  prove	  that	  using	  CT	  will	  enhance	  the	  possibility	  of	  early	  detection	  of	  
mesothelioma	  in	  high-­‐risk	  people	  with	  prior	  asbestos	  exposure.	  We	  are	  conducting	  this	  
study	  in	  people	  who	  have	  been	  exposed	  to	  asbestos	  at	  least	  20	  years	  ago,	  and/or	  do	  have	  
pleural	  plaques,	  a	  population	  at	  high	  risk	  of	  mesothelioma	  and	  lung	  cancer.	  You	  have	  
been	  invited	  to	  participate	  in	  this	  study	  because	  of	  your	  asbestos	  history.	  
Secondly,	  there	  is	  evidence	  in	  other	  types	  of	  cancers	  such	  as	  cancers	  of	  the	  prostate	  and	  
ovary,	  that	  analysis	  of	  blood	  may	  reveal	  protein	  markers	  that	  indicate	  the	  presence	  of	  
cancer	  in	  the	  body.	  A	  companion	  blood	  analysis	  study	  is	  being	  undertaken	  in	  an	  effort	  to	  
discover	  such	  markers	  for	  lung	  cancer	  and	  mesothelioma,	  so	  that	  the	  accuracy	  of	  CT-­‐scan	  
diagnosis	  for	  lung	  cancer	  may	  be	  further	  improved.	  
	  
Thirdly,	  Pulmonary	  Function	  Testing	  (PFT)	  has	  been	  suggested	  as	  useful	  tools	  to	  follow	  
people	  who	  have	  been	  exposed	  to	  asbestos.	  
PFT’s	  (breathing	  test)	  will	  be	  combined	  with	  CT-­‐scan	  (blood	  and	  sputum)	  information	  to	  
study	  ways	  to	  improve	  our	  screening	  process.	  
	  
Additionally,	  there	  is	  evidence	  that	  the	  analysis	  of	  sputum	  using	  a	  new	  test	  -­‐	  called	  
LungAlert™,	  developed	  by	  the	  company	  International	  Medical	  Innovations,	  Inc.	  -­‐	  also	  can	  
reliably	  detect	  lung	  cancer.	  This	  part	  of	  the	  study	  will	  examine	  if	  this	  test	  can	  distinguish	  
cancer	  from	  other	  lung	  diseases	  and	  from	  healthy	  lungs,	  in	  a	  screening	  population.	  In	  a	  pilot	  
study	  the	  LungAlert™	  	  test	  was	  able	  to	  detect	  over	  80%	  of	  lung	  cancers.	  
This	  analysis	  of	  your	  blood	  and	  sputum	  is	  compared	  to	  the	  results	  of	  the	  CT	  scan.	  The	  
purpose	  of	  this	  study	  is	  to	  assess	  whether	  the	  results	  from	  the	  blood	  or	  sputum	  analysis	  are	  
in	  agreement	  with,	  or	  complementary	  to	  the	  CT	  results,	  and	  whether	  they	  help	  reducing	  the	  
false	  positive	  results	  from	  the	  screening	  CT.	  Long-­‐term	  goal	  would	  be	  to	  develop	  a	  non-­‐
invasive,	  and	  inexpensive	  screening	  tool	  which	  does	  not	  require	  complex	  technology	  and	  
special	  visits	  to	  health	  centres.	  	  
	  
Procedures	  
If	  you	  decide	  to	  take	  part	  in	  the	  screening	  study,	  you	  will	  be	  asked	  to	  answer	  a	  
questionnaire	  about	  your	  occupational	  and	  smoking	  history,	  as	  well	  as	  basic	  demographic	  
information.	  The	  completion	  of	  the	  consent	  and	  the	  questionnaire	  might	  take	  5	  –	  30	  mins,	  
depending	  on	  the	  questions	  you	  may	  have.	  The	  sampling	  of	  blood	  and	  serum	  will	  take	  no	  
longer	  than	  10-­‐15	  mins,	  the	  same	  amount	  of	  time	  might	  be	  needed	  for	  the	  CT	  study	  itself.	  
	  
	  The	  PFT	  (breathing	  test)	  will	  take	  approximately	  10	  minutes.	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Including	  waiting	  times,	  you	  should	  allocate	  up	  to	  2	  hours	  in	  the	  hospital,	  however,	  most	  
likely	  it	  will	  be	  faster	  than	  that.	  Your	  participation	  in	  the	  research	  study	  begins	  at	  the	  time	  
of	  your	  signature.	  	  
	  
A	  screening	  CT	  examination,	  also	  called	  CAT	  scan,	  of	  the	  lungs	  will	  be	  performed	  without	  
intravenous	  contrast.	  The	  CT	  examination	  as	  such	  is	  not	  an	  experimental	  procedure,	  CAT	  
scans	  are	  performed	  routinely	  since	  decades.	  However,	  in	  your	  particular	  case,	  this	  albeit	  
standard	  examination	  is	  performed	  for	  the	  purposes	  of	  research	  only,	  it	  is	  not	  part	  of	  
standard	  of	  care.	  The	  screening	  CT	  examination	  of	  the	  lungs	  takes	  less	  than	  10-­‐20	  minutes	  
to	  perform.	  You	  will	  be	  asked	  to	  remove	  your	  upper	  body	  garments	  and	  wear	  a	  gown	  that	  
would	  be	  left	  on	  during	  the	  procedure.	  You	  will	  not	  be	  required	  to	  have	  any	  injections,	  
take	  any	  medications	  by	  mouth	  or	  apply	  any	  to	  your	  body.	  
If	  no	  abnormalities	  are	  found	  on	  the	  initial	  examinations,	  you	  will	  be	  examined	  with	  one	  
repeat	  screening	  CT	  of	  the	  chest	  after	  one	  year.	  	  
If	  pleural	  plaques	  or	  a	  nodule	  in	  the	  lungs	  is	  seen	  on	  your	  baseline	  CT,	  this	  will	  lead	  to	  
further	  testing.	  Quite	  likely	  (approximately	  1	  in	  3	  chance),	  you	  will	  be	  invited	  for	  a	  follow-­‐
up	  CT	  3	  or	  6	  months.	  Further	  investigations	  will	  be	  chosen	  according	  to	  standard	  of	  care	  
and	  will	  be	  explained	  to	  you	  at	  the	  time.	  These	  will	  be	  coordinated	  by	  your	  physician	  with	  
Dr.	  Marc	  de	  Perrot,	  Department	  of	  Thoracic	  Surgery.	  	  
	  
Both	  at	  the	  time	  of	  your	  baseline	  screening	  CT	  and	  at	  your	  annual	  follow-­‐up	  screening	  CT,	  
you	  will	  be	  asked	  to	  provide	  5	  ml	  (approximately	  2	  teaspoons	  full)	  blood	  sample	  through	  a	  
needle	  stick.	  A	  blood-­‐taking	  technician	  employed	  by	  the	  University	  Health	  Network	  or	  a	  
certified	  nurse	  will	  carry	  out	  this	  procedure.	  Purpose	  of	  this	  study	  is	  to	  search	  in	  the	  blood	  
for	  so-­‐called	  “markers”,	  substances	  in	  the	  blood	  which	  indicate	  that	  there	  is	  a	  cancer	  in	  the	  
lungs	  or	  pleura.	  Most	  of	  these	  markers	  are	  still	  in	  development,	  thus	  your	  blood	  will	  be	  
stored	  and	  analyzed	  at	  a	  future	  date.	  	  
You	  will	  also	  be	  asked	  to	  provide	  a	  sputum	  sample	  to	  the	  study	  nurse	  by	  coughing	  up	  
sputum	  /	  phlegm	  into	  a	  cup.	  Most	  likely	  you	  will	  be	  able	  to	  produce	  sputum	  spontaneously.	  
If	  you	  cannot	  voluntarily	  produce	  sputum,	  no	  further	  measures	  are	  taken.	  There	  are	  no	  
dietary	  restrictions	  or	  other	  preparations	  required	  prior	  to	  the	  test.	  The	  sputum	  sample	  will	  
then	  be	  sent	  to	  a	  laboratory	  to	  be	  tested	  for	  the	  presence	  of	  a	  sugar	  molecule	  that	  is	  
believed	  to	  be	  associated	  with	  lung	  cancer.	  Purpose	  of	  this	  study	  is	  to	  see	  whether	  these	  
sugars	  can	  indicate	  the	  presence	  of	  a	  cancer	  in	  the	  lungs	  or	  pleura.	  	  
	  
You	  will	  be	  asked	  to	  have	  a	  PFT	  (breathing	  test).	  You	  will	  take	  deep	  breathes	  and	  blow	  into	  
a	  mouthpiece	  connected	  to	  a	  machine	  known	  as	  a	  spirometer.	  The	  machine	  measures	  how	  
forceful	  and	  how	  much	  air	  you	  can	  blow	  in	  each	  breath.	  
Spirometry	  will	  be	  conducted	  using	  a	  flow-­‐sensitive	  spirometer	  (Presto	  Flash	  Portable	  
Spirometer	  Version	  1.2)	  To	  estimate	  lung	  function,	  we	  will	  use	  bother	  forced	  expiratory	  
volume	  in	  1	  second	  (FEV)	  and	  forced	  vital	  capacity	  (FVC).	  	  
	  
	  
Risks	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The	  risk	  associated	  with	  the	  screening	  CT	  scan	  is	  attributable	  to	  radiation.	  The	  screening	  
study	  is	  using	  CAT	  scans	  with	  recent	  technology	  that	  allows	  for	  a	  significant	  reduction	  in	  
radiation	  dose.	  This	  brings	  the	  radiation	  dose	  from	  the	  CAT	  scan	  down	  to	  a	  level	  that	  is	  
significantly	  less	  than	  standard	  chest	  CT	  and	  closer	  to	  two	  views	  of	  the	  chest,	  as	  you	  might	  
have	  for	  a	  chest	  x-­‐ray.	  For	  the	  screening	  CT,	  the	  radiation	  dose	  of	  the	  CT	  scan	  is	  less	  than	  2	  
rads.	  Annual	  radiation	  from	  environment	  is	  100-­‐200	  mrads.	  The	  radiation	  dose	  of	  the	  
repeat	  screening	  CT	  scan	  is	  the	  same	  as	  the	  first	  CT	  scan.	  
Screening	  may	  lead	  to	  a	  cascade	  of	  further	  evaluations	  and	  potential	  complications.	  Since	  
a	  CT	  scan	  is	  a	  more	  sensitive	  test	  for	  pleura	  and	  lung	  abnormalities,	  more	  abnormalities	  
will	  be	  detected	  than	  on	  a	  chest	  x-­‐ray.	  Many	  of	  these	  may	  be	  benign,	  that	  is,	  not	  
malignant	  (i.e.	  not	  cancer).	  
Given	  all	  the	  different	  tests	  that	  may	  have	  to	  be	  performed	  after	  your	  initial	  screening	  
study,	  it	  may	  take	  a	  few	  months	  to	  finally	  determine	  whether	  the	  plaque	  or	  nodule	  is	  
benign,	  or	  whether	  you	  really	  have	  cancer	  or	  mesothelioma.	  This	  time	  period	  following	  
the	  initial	  positive	  screening	  result	  will	  be	  full	  of	  anxiety,	  insecurity	  and	  fear,	  which	  might	  
be	  difficult	  to	  deal	  with.	  If	  you	  feel	  anxious	  at	  any	  time	  during	  your	  participation	  in	  the	  
study,	  please	  contact	  the	  study	  staff	  or	  the	  investigator	  involved	  in	  this	  study,	  at	  any	  time,	  
to	  discuss	  your	  concerns	  and	  feelings.	  	  
CT	  is	  an	  unproven	  technology	  for	  screening	  for	  mesothelioma	  and	  lung	  cancer.	  It	  is	  
therefore	  possible	  that	  you	  could	  have	  a	  negative	  CT	  screening	  study	  and	  still	  develop	  
mesothelioma	  or	  lung	  cancer	  and	  die	  from	  it.	  Furthermore,	  despite	  best	  efforts,	  small	  
carcinomas	  may	  be	  missed.	  Finally,	  given	  the	  nature	  of	  CT,	  lung	  cancer	  screening	  with	  CT	  
targets	  small	  cancers	  in	  the	  periphery	  of	  the	  lung,	  and	  it	  is	  fully	  expected	  to	  miss	  some	  
centrally	  located	  cancers.	  
A	  study	  conducted	  and	  published	  by	  this	  group	  of	  Cornell	  investigators	  has	  shown	  that	  
this	  type	  of	  CT	  scan	  can	  diagnose	  lung	  cancer	  much	  earlier	  than	  other	  methods	  currently	  
in	  use.	  The	  use	  of	  CT	  in	  the	  diagnosis	  of	  mesothelioma	  is	  new.	  We	  cannot	  promise	  that	  
you	  will	  receive	  any	  benefits	  from	  this	  study.	  Using	  the	  CT	  examination,	  a	  more	  sensitive	  
diagnostic	  procedure,	  you	  may	  have	  greater	  chances	  of	  detection	  of	  an	  early	  abnormality	  
of	  your	  lungs,	  but	  this	  cannot	  be	  guaranteed,	  cancers	  still	  may	  be	  missed.	  Screening	  is	  no	  
substitute	  for	  tobacco	  avoidance,	  and	  it	  is	  not	  known	  whether	  screening	  leads	  to	  better	  
outcomes.	  
	  
The	  risk	  associated	  with	  the	  blood	  taking	  includes	  discomfort	  with	  the	  needle	  stick	  and	  
possible	  slight	  bruising	  at	  the	  needle	  puncture	  site.	  	  
	  
There	  is	  no	  risk	  associated	  with	  the	  sputum	  collection	  or	  with	  the	  PFT	  (breathing	  test).	  	  
	  
Benefits	  
You	  may	  or	  may	  not	  receive	  any	  medical	  benefit	  from	  your	  participation	  in	  this	  study.	  
Information	  learned	  from	  this	  study	  may	  benefit	  other	  patients	  in	  the	  future	  with	  your	  
disease.	  
	  
Confidentiality	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Participation	  in	  research	  in	  general	  may	  involve	  loss	  of	  privacy.	  For	  study	  purposes,	  all	  
data	  from	  your	  exam	  with	  your	  personal	  identifiers	  removed	  is	  immediately	  entered	  into	  
the	  web-­‐based	  interactive	  system.	  	  
Any	  information	  obtained	  during	  this	  study	  and	  identified	  with	  you	  will	  remain	  
confidential	  and	  will	  be	  disclosed	  only	  with	  your	  permission.	  Information	  regarding	  the	  
results	  of	  your	  tests	  will	  be	  sent	  back	  to	  you	  and	  your	  referring	  physician	  only.	  Any	  further	  
information	  including	  previous	  radiologic	  or	  any	  follow-­‐up	  studies	  would	  be	  sent	  to	  the	  
responsible	  investigator	  by	  your	  physician	  (your	  primary	  physician,	  your	  GP,	  or	  a	  specialist	  
responsible	  for	  your	  treatment)	  as	  this	  information	  is	  important	  for	  the	  study	  evaluation.	  
This	  includes	  follow-­‐up	  diagnostic	  CTs,	  biopsy	  and	  surgical	  results/reports	  and	  pathologic	  
slides	  associated	  with	  such	  procedures.	  This	  information	  remains	  confidential	  and	  
becomes	  part	  of	  your	  study	  file	  as	  documentation	  or	  follow-­‐up	  to	  findings	  detected	  on	  
your	  screening	  CT(s)	  scan.	  With	  your	  signature,	  you	  give	  permission	  to	  the	  PI	  and	  his	  staff	  
to	  have	  access	  to	  your	  health	  records.	  
No	  names	  or	  identifying	  information	  will	  be	  used	  in	  any	  publication	  or	  presentations.	  No	  
information	  identifying	  you	  will	  be	  transferred	  outside	  your	  primary	  physician	  and	  the	  
study	  doctor	  at	  UHN.	  	  
Data	  acquired	  during	  this	  study	  will	  be	  sent	  to	  your	  referring	  physician	  or	  occupational	  
health	  clinic,	  and	  will	  also	  be	  linked	  to	  your	  permanent	  medical	  record	  at	  UHN.	  
	  
Participation	  
Your	  participation	  in	  this	  study	  is	  voluntary.	  You	  can	  choose	  not	  to	  participate	  or	  you	  may	  
withdraw	  at	  any	  time	  without	  affecting	  your	  medical	  care.	  	  
If	  you	  wish	  to	  withdraw,	  you	  need	  to	  inform	  both	  the	  study	  doctor	  at	  UHN	  (Dr.	  Patsios)	  
and	  your	  primary/family	  physician,	  since	  both	  are	  involved	  in	  the	  data	  collection.	  
If	  you	  decide	  to	  withdraw	  from	  the	  study,	  regular	  clinical	  care	  will	  carry	  on	  for	  your	  
condition.	  This	  regular	  clinical	  care	  is	  the	  same	  that	  you	  would	  have	  if	  you	  would	  decide	  to	  
stay	  in	  the	  study.	  After	  your	  withdrawal,	  no	  more	  data	  will	  be	  collected	  for	  research	  
purposes	  and	  transferred	  outside	  the	  treating	  physician(s).	  	  
	  
Additional	  Analyses	  
Given	  the	  large	  number	  of	  potential	  candidates	  for	  the	  screening	  study,	  several	  
companies	  are	  developing	  semi-­‐automated	  software	  tools	  for	  the	  detection	  of	  pleural	  
plaques	  and	  lung	  nodules	  on	  a	  screening	  CT.	  We	  are	  collaborating	  with	  a	  few	  companies,	  
testing	  their	  products	  for	  validity,	  accuracy	  and	  usefulness	  in	  a	  screening	  situation.	  They	  
get	  a	  general	  feedback,	  consisting	  of	  overall	  analyses	  and	  statistics.	  Occasionally,	  
anonymous	  data	  and	  selected	  images	  might	  be	  sent	  to	  the	  companies	  for	  problem-­‐solving	  
or	  general	  interest.	  Any	  identifying	  information	  will	  be	  removed	  from	  such	  images	  before	  
sending	  them	  to	  the	  company.	  	  
	  
As	  laboratory	  technology	  develops,	  more	  sophisticated	  techniques	  may	  be	  developed	  to	  
analyze	  more	  precisely	  the	  various	  components	  of	  sputum	  or	  blood.	  In	  addition,	  there	  is	  
evidence	  that	  the	  genetic	  make-­‐up	  of	  an	  individual	  may	  affect	  the	  predisposition	  of	  a	  
person	  to	  asbestos-­‐induced	  mesothelioma	  and	  lung	  cancer.	  It	  is	  possible	  that	  your	  sputum	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or	  blood	  sample	  may	  be	  suitable	  for	  use	  in	  such	  studies.	  We	  ask	  your	  permission	  to	  allow	  
the	  use	  of	  your	  sample	  for	  future	  studies.	  Such	  research	  will	  be	  conducted	  only	  after	  the	  
UHN	  Research	  Ethics	  Board	  has	  approved	  the	  study.	  All	  conditions	  contain	  in	  this	  Consent	  
Form	  will	  apply	  to	  such	  studies.	  The	  results	  of	  these	  studies	  will	  not	  be	  put	  in	  your	  health	  
records.	  	  
	  
My	  sputum	  and	  blood	  samples	  may	  be	  banked	  for	  future	  research	  purposes	  
 YES	  
 NO	  
	  
	  
Alternatives	  
While	  the	  screening	  CTs	  would	  not	  normally	  be	  performed	  in	  your	  situation,	  the	  clinical	  
follow-­‐up	  for	  any	  identified	  abnormality	  might	  be	  done	  even	  if	  you	  were	  not	  participating	  
in	  this	  study.	  
	  
Costs	  	  
You	  will	  be	  reimbursed	  for	  parking	  and	  transportation	  costs,	  as	  confirmed	  by	  receipts.	  
Neither	  you	  nor	  your	  insurance	  carrier	  will	  be	  billed	  for	  either	  the	  professional	  or	  
technical	  fees	  for	  the	  screening	  CT	  scan.	  However,	  if	  an	  abnormality	  is	  found	  on	  the	  
screening	  CT,	  the	  additional	  studies	  are	  clinically	  indicated,	  and	  thus,	  you	  will	  be	  billed	  
according	  to	  standard	  procedures	  (either	  through	  your	  medical	  insurance	  and/or	  other	  
forms	  of	  medical	  coverage).	  
	  
Compensation	  
If	  you	  become	  ill	  or	  are	  physically	  injured	  as	  a	  result	  of	  participation	  in	  this	  study,	  medical	  
treatment	  will	  be	  provided.	  The	  reasonable	  costs	  of	  such	  treatment	  beyond	  that	  provided	  
by	  your	  insurance	  will	  be	  covered	  by	  your	  health	  insurance	  for	  any	  injury	  or	  illness	  that	  is	  
directly	  a	  result	  of	  participation	  in	  this	  trial.	  In	  no	  way	  does	  signing	  this	  consent	  form	  
waive	  your	  legal	  rights	  nor	  does	  it	  relieve	  the	  investigators,	  sponsors	  or	  involved	  
institutions	  from	  their	  legal	  and	  professional	  responsibilities.	  	  
	  
Questions	  	  
If	  you	  have	  any	  questions	  about	  your	  rights	  as	  a	  research	  participant,	  or	  if	  you	  have	  any	  
general	  questions	  about	  the	  study,	  you	  may	  call	  Dr.	  Demetris	  Patsios	  at	  416-­‐586-­‐4200	  ext.	  
5598.	  
	  
If	  you	  have	  any	  questions	  about	  your	  rights	  as	  a	  research	  participant,	  please	  call	  Dr.	  R.	  
Heslegrave,	  Chair	  	  Research	  Ethics	  Board	  at	  (416)	  340-­‐4557.	  This	  person	  is	  not	  involved	  
with	  the	  research	  project	  in	  any	  way	  and	  calling	  him	  will	  not	  affect	  your	  participation	  in	  
the	  study.	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Consent	  	  
You	  have	  had	  the	  opportunity	  to	  discuss	  this	  study	  and	  your	  questions	  have	  been	  
answered	  to	  your	  satisfaction.	  You	  consent	  to	  take	  part	  in	  the	  study	  with	  the	  
understanding	  that	  you	  may	  withdraw	  at	  any	  time	  without	  affecting	  my	  medical	  care.	  You	  
have	  received	  a	  signed	  copy	  of	  this	  consent	  form.	  You	  voluntarily	  consent	  to	  participate	  in	  
this	  study.	  	  
	  
Please	  check	  below	  which	  part(s)	  of	  the	  research	  study	  you	  do	  consent	  to:	  
 I	  consent	  to	  participate	  in	  the	  following	  in	  addition	  to	  the	  low-­‐dose	  CT	  study	  
 the	  blood	  sampling	  
 the	  sputum	  sampling	  
 the	  PFT	  (breathing	  test)	  
 I	  consent	  to	  participate	  in	  the	  low-­‐dose	  CT	  study	  only	  
	  
	  
	  
__________________________	   ______________________	   __________________	  
Patient’s	  Name	  (Please	  Print)	   	  Patient’s	  Signature	  	   Date	  	  
	  
	  
I	  confirm	  that	  I	  have	  explained	  the	  nature	  and	  purpose	  of	  the	  study	  to	  the	  subject	  
named	  above.	  I	  have	  answered	  all	  questions.	  	  
	  
	  
___________________________	   ______________________	   ___________________	  
Name	  of	  Person	  	   Signature	  	   Date	  
Obtaining	  Consent	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APPENDIX B- Sample of Database and Variables Extracted From Subjects of 
the Early Diagnosis of Mesothelioma and Lung Cancer in Prior Asbestos Workers 
Study  
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APPENDIX C- Sample of Pulmonary Function Test From a Subject in the Early 
Diagnosis of Mesothelioma and Lung Cancer in Prior Asbestos Workers Study  
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APPENDIX D 
 
Lowess Curves for Continuous Variables Not Included in Predictive Models  
Y-axis for each graph refers to the probability of pulmonary fibrosis by LDCT. Black 
dots at the probability mark of 1 refer to cases. Black dots at the probability mark of 0 
refer to controls. The x axis refers to various pulmonary function test variables. On each 
page is a set of pre- and post-bronchodilator curves.  
 
 
 
Prefvc = pre-bronchodilator forced vital capacity 
 
Postfvc= post-bronchodilator forced vital capacity 
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Prefev1= pre-bronchodilator forced expiratory volume in 1 second 
 
Postfev1= post-bronchodilator forced expiratory volume in 1 second 
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Pre fev1_fvc = pre-bronchodilator FEV1/FVC 
 
 
Postfev1_fvc = post-bronchodilator FEV1/FVC 
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TLC = total lung capacity 
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DLCO = Diffusing Lung Capacity  
 
 
DLCO_VA = Difusing Lung Capacity, adjusted for volume 
0
.2
.4
.6
.8
1
ct
fib
ro
si
s0
0 50 100 150
dlco_
bandwidth = .8
Lowess smoother
0
.2
.4
.6
.8
1
ct
fib
ro
si
s0
0 50 100 150 200
dlco_va_
bandwidth = .8
Lowess smoother
	  
	  
119	  
	  
 
 
PK-YR = pack-years of cigarette smoking
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Height_meters = Height in meters 
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Exposure_year_calc = Number of Years exposed to Asbestos 
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Ex_start_age = Age at start of exposure to Asbestos 
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APPENDIX E 
Histograms of all PFT variables 
Y-axis= density which scales the height of the bars so that the sum of their areas equals 1. 
 
 
Pre-FVC = pre bronchodilator forced vital capacity 
 
Post-FVC= post bronchodilator forced vital capacity. This variable was included in the 
final predictive model. 
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Pre-FEV1- pre bronchodilator forced expiratory volume in 1 second  
 
Post-FEV1- post bronchodilator forced expiratory volume in 1 second. This variable was 
included in thre final predictive model. 
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Prefev1_fvc= pre bronchodilator FEV1/FVC 
 
 
Postfev1_fvc= post bronchodilator FEV1/FVC  
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Tlc= total lung capacity  
 
 
Dlco= diffusing lung capacity  
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Dlco_va= Difusing Lung Capacity, adjusted for volume 
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APPENDIX F 
 
 
Predictive Logistic Model for Asbestosis in a Cohort of Asbestos Workers Stratified by 
Smoking Status (nsmoke=248; nnosmoke= 65)  
 
 Smokers  Non Smokers  
 OR (95%CI) p Value OR (95%CI) p 
Value 
Age (10years)  1.41 (0.88-2.26) 0.149 0.75 (0.17-3.22) 0.703 
Age first asbestos 
exposure (years)  
0.98 (0.92-1.04) 0.518 0.95 (0.58-1.55) 0.845 
Dyspnea  2.06 (0.94-4.50) 0.070 OMITTED  
Post FVC Spline (%) 0.95 (0.88-1.02) 0.230 1.11 (0.56-2.18) 0.758 
 0.87 (0.67-1.14) 0.315 0.68 (0.08-5.74) 0.721 
 2.05 (0.62-6.75) 0.235 0.09 (9.41e-07-10471.6) 0.695 
Post FEV1 Spline (%)  0.96 (0.91-1.01) 0.191 11.05 ( 0.14-834.98) 0.276 
 1.21 (1.00-1.46) 0.045 0.03 (0.0000752-14.42) 0.271 
 0.42 (0.13-1.26) 0.122 4789211 (0.0001043-
2.20e+17) 
0.219 
BMI Splines  0.88 (0.67-1.17) 0.403 0.67 (0.18-2.39) 0.537 
 2.09 (0.59-7.43) 0.250 4.93 (0.02-1366.88) 0.578 
 0.08 (0.00-5.82) 0.254 0.001 (4.53e-12-228258.2) 0.482 
Pleural Plaques  1.69 (0.71-3.99) 0.232 4.38 (0.17-110.34) 0.369 
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APPENDIX G 
R printout for calibration (Modeling and associated graphs) 
 
 
> ls() 
[1] "ASB12FEB10" 
> attach(ASB12FEB10) 
> library(Design) 
Loading required package: Hmisc 
Loading required package: survival 
Loading required package: splines 
 
Attaching package: 'Hmisc' 
 
 
        The following object(s) are masked from package:survival : 
 
         untangle.specials  
 
 
        The following object(s) are masked from package:base : 
 
         format.pval, 
         round.POSIXt, 
         trunc.POSIXt, 
         units  
 
Design library by Frank E Harrell Jr 
 
Type library(help='Design'), ?DesignOverview, or ?Design.Overview') 
to see overall documentation. 
 
 
Attaching package: 'Design' 
 
 
        The following object(s) are masked from package:Hmisc : 
 
         strgraphwrap  
 
 
        The following object(s) are masked from package:survival : 
 
         Surv  
 
 
> Mfull <- lrm(case ~ age +  ex_start_age + rcs(FVCpost, 5) + rcs(FEV1post, 5) 
+ dyspnea + PPlaque + smkdi , x=T, y=T) 
> anova(Mfull) 
                Wald Statistics          Response: case  
 
 Factor          Chi-Square d.f. P      
 age              2.37       1   0.1239 
 ex_start_age     0.75       1   0.3854 
 FVCpost         15.85       4   0.0032 
  Nonlinear       5.71       3   0.1265 
 FEV1post         9.66       4   0.0466 
  Nonlinear       7.66       3   0.0537 
 dyspnea          1.55       1   0.2136 
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 PPlaque          1.42       1   0.2342 
 smkdi            3.18       1   0.0744 
 TOTAL NONLINEAR 13.59       6   0.0346 
 TOTAL           27.14      13   0.0119 
> valMfull <- validate(Mfull, B=200) 
> print(valMfull) 
            index.orig     training        test    optimism index.corrected   n 
Dxy        0.498455033  0.567392375  0.42174337  0.14564900      0.35280603 200 
R2         0.181137632  0.242080843  0.12834741  0.11373343      0.06740420 200 
Intercept  0.000000000  0.000000000 -0.52285854  0.52285854     -0.52285854 200 
Slope      1.000000000  1.000000000  0.66806099  0.33193901      0.66806099 200 
Emax       0.000000000  0.000000000  0.20052786  0.20052786      0.20052786 200 
D          0.099793603  0.136722585  0.06882148  0.06790111      0.03189249 200 
U         -0.006079027 -0.006079027  0.01912317 -0.02520220      0.01912317 200 
Q          0.105872630  0.142801612  0.04969830  0.09310331      0.01276932 200 
B          0.097939677  0.092189467  0.10446826 -0.01227880      0.11021847 200 
> print(Mfull) 
 
Logistic Regression Model 
 
lrm(formula = case ~ age + ex_start_age + rcs(FVCpost, 5) + rcs(FEV1post,  
    5) + dyspnea + PPlaque + smkdi, x = T, y = T) 
 
 
Frequencies of Responses 
  0   1  
286  43  
 
Frequencies of Missing Values Due to Each Variable 
        case          age ex_start_age      FVCpost     FEV1post      dyspnea      
PPlaque        smkdi  
           4            4           15          276          276            0            
0            1  
 
       Obs  Max Deriv Model L.R.       d.f.          P          C        Dxy      
Gamma      Tau-a         R2      Brier  
       329      4e-07      33.83         13     0.0013      0.749      0.499      
0.501      0.114      0.181      0.098  
 
             Coef      S.E.    Wald Z P      
Intercept     1.723607 3.63904  0.47  0.6358 
age           0.032516 0.02113  1.54  0.1239 
ex_start_age -0.023682 0.02728 -0.87  0.3854 
FVCpost      -0.081035 0.03955 -2.05  0.0405 
FVCpost'      0.228473 0.25923  0.88  0.3781 
FVCpost''    -2.333374 1.57056 -1.49  0.1374 
FVCpost'''    4.749910 2.49301  1.91  0.0567 
FEV1post      0.006554 0.03194  0.21  0.8374 
FEV1post'    -0.075493 0.14468 -0.52  0.6018 
FEV1post''    2.046558 1.28054  1.60  0.1100 
FEV1post'''  -4.794087 2.39876 -2.00  0.0457 
dyspnea       0.463526 0.37267  1.24  0.2136 
PPlaque       0.457993 0.38499  1.19  0.2342 
smkdi         0.960487 0.53842  1.78  0.0744 
 
> calMfull <- calibrate(Mfull, B=200) 
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> plot(calMfull) 
 
n=329   Mean absolute error=0.02233329   Mean squared error=0.0008027235 
0.9 Quantile of absolute error=0.04566853 
 
>
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_______________________________________________________________________________  
 
 
> Mnest <- lrm(case ~ age + rcs(FVCpost, 5) + rcs(FEV1post, 5)  + smkdi , x=T, 
y=T) 
> print(Mnest) 
 
Logistic Regression Model 
 
lrm(formula = case ~ age + rcs(FVCpost, 5) + rcs(FEV1post, 5) +  
    smkdi, x = T, y = T) 
 
 
Frequencies of Responses 
  0   1  
294  44  
 
Frequencies of Missing Values Due to Each Variable 
    case      age  FVCpost FEV1post    smkdi  
       4        4      276      276        1  
 
       Obs  Max Deriv Model L.R.       d.f.          P          C        Dxy      
Gamma      Tau-a         R2      Brier  
       338      1e-08      27.07         10     0.0025      0.728      0.456      
0.458      0.104      0.143      0.101  
 
            Coef      S.E.    Wald Z P      
Intercept    0.378523 3.47921  0.11  0.9134 
age          0.034627 0.01991  1.74  0.0820 
FVCpost     -0.069925 0.03789 -1.85  0.0650 
FVCpost'     0.262213 0.24312  1.08  0.2808 
FVCpost''   -2.270407 1.48738 -1.53  0.1269 
FVCpost'''   4.278024 2.38060  1.80  0.0723 
FEV1post     0.008956 0.02923  0.31  0.7593 
FEV1post'   -0.119635 0.13619 -0.88  0.3797 
FEV1post''   2.118481 1.23529  1.71  0.0864 
FEV1post''' -4.595765 2.32739 -1.97  0.0483 
smkdi        1.069385 0.52627  2.03  0.0422 
 
> anova(Mnest) 
                Wald Statistics          Response: case  
 
 Factor          Chi-Square d.f. P      
 age              3.02       1   0.0820 
 FVCpost         10.77       4   0.0293 
  Nonlinear       4.03       3   0.2587 
 FEV1post         7.14       4   0.1289 
  Nonlinear       6.27       3   0.0991 
 smkdi            4.13       1   0.0422 
 TOTAL NONLINEAR 10.86       6   0.0929 
 TOTAL           22.79      10   0.0116 
> valMnest <- validate(Mnest, B=200) 
> print(valMnest) 
           index.orig    training        test     optimism index.corrected   n 
Dxy        0.45562771  0.51038730  0.39053185  0.119855454      0.33577225 200 
R2         0.14289608  0.19105034  0.10230177  0.088748561      0.05414752 200 
Intercept  0.00000000  0.00000000 -0.51995347  0.519953470     -0.51995347 200 
Slope      1.00000000  1.00000000  0.69211955  0.307880450      0.69211955 200 
Emax       0.00000000  0.00000000  0.19202211  0.192022106      0.19202211 200 
D          0.07712528  0.10639249  0.05379094  0.052601555      0.02452373 200 
U         -0.00591716 -0.00591716  0.01397733 -0.019894492      0.01397733 200 
Q          0.08304244  0.11230965  0.03981361  0.072496046      0.01054640 200 
B          0.10127403  0.09823886  0.10613952 -0.007900658      0.10917468 200 
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> calMnest <- calibrate(Mnest, B=200) 
> plot(calMnest) 
 
n=338   Mean absolute error=0.02314374   Mean squared error=0.0008741606 
0.9 Quantile of absolute error=0.05359642 
 
> plot(calMnest) 
 
n=338   Mean absolute error=0.02314374   Mean squared error=0.0008741606 
0.9 Quantile of absolute error=0.05359642 
 
> 
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logistic ctfibrosis0  age10 dyspnea  pleural_plaques   fvc1 fvc2 fvc3 fvc4 fev11 fev12 
fev13 fev14    asbdurdi29 smkdi  
>  asbdur_smoke 
 
 
. predict Pfull, p 
(277 missing values generated) 
 
. logistic ctfibrosis0  age10 dyspnea  pleural_plaques   fvc1 fvc2 fvc3 fvc4 fev11 fev12 
fev13 fev14    asbdurdi29 smkdi  
> if e(sample) 
 
 
. predict Pint, p 
(277 missing values generated) 
 
. roccomp ctfibrosis0 Pfull Pint 
 
                              ROC                    -Asymptotic Normal-- 
                   Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------------------- 
Pfull              338     0.7447       0.0441        0.65825     0.83108 
Pint               338     0.7342       0.0461        0.64389     0.82441 
------------------------------------------------------------------------- 
Ho: area(Pfull) = area(Pint) 
    chi2(1) =     1.11       Prob>chi2 =   0.2922 
 
. roccomp ctfibrosis0 Pfull Pint, graph 
 
 
DICHOTOMIZE VARIABLE 
. generate asbdurdi29=0 
 
. replace asbdurdi29=1 if   exposure_year_calc>29 
(307 real changes made) 
 
. generate asbdur_smoke=  asbdurdi29* smkdi 
 
 
 
 
 
 
 
 
 
